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Abstract 
A LONGITUDINAL STUDY OF THE MOTIVATIONS FOR THE NON-MEDICAL USE OF 
PRESCRIPTION DRUGS IN A NATIONAL SAMPLE OF YOUNG ADULTS 
 
By:  Tess K. Drazdowski, M.S. 
 
A dissertation submitted in partial fulfillment of the requirements for the degree of Doctor of 
Philosophy at Virginia Commonwealth University. 
 
Virginia Commonwealth University, 2016. 
 
Major Director: Wendy L. Kliewer, Ph.D., Chair and Professor of Psychology, Department of 
Psychology 
 
Young adults are most at-risk for the non-medical use of prescription drugs (NMUPD) and many 
of its associated negative consequences. Understanding this population’s motivations for use can 
help to inform efforts to reduce NMUPD. Past research has been limited in scope, consisting 
primarily of cross-sectional work with college students focusing on prescription stimulants. The 
current study researched how motivations for NMUPD changed over young adulthood using 
three waves of data from a longitudinal, nationally representative sample of 14,990 19 to 24 year 
olds in the Monitoring the Future study cohorts collected between 1976 to 2013. Prescription 
stimulants, central nervous system (CNS) depressants, and opioids were investigated, along with 
sex and college attendance as potential moderators. Differences in NMUPD motivations for 
young adults who initiated NMUPD in high school versus in early young adulthood were 
studied. Additionally, motivation patterns of new users were investigated. Analyses indicated 
that both recreational and self-treatment motivations commonly were reported over time and 
across drug classes, with four to five popular motivations acknowledged in each class. In 
general, generalized estimated equations repeated measure analyses found that NMUPD 
motivations remained relatively stable across young adulthood, with some reductions for the 
    ix 
 
 
motivations of experimentation and boredom, and an increase in select self-treatment 
motivations. Overall, men were more likely to endorse recreational motivations, while women 
were more likely to endorse self-treatment motivations, though this varied somewhat by 
prescription drug class. Young adults not enrolled in college courses were more likely to endorse 
using stimulants non-medically for different reasons than their peers who were enrolled. There 
also were differences in motivations based on if young adults initiated NMUPD in high school 
compared to when they were 19/20 years old. However, motivations were fairly consistent across 
young adult development regardless of when NMUPD was initiated. These data suggest that 
efforts aimed at preventing or reducing NMUPD in young adult populations should include 
targets to reduce both self-treatment and recreational motivations; may need to be tailored by 
prescription drug class, sex, and college attendance status; could start in high school; and can be 
used for new and continued users across young adulthood.  
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A Longitudinal Study of the Motivations for the Non-medical Use of Prescription Drugs 
in a National Sample of Young Adults 
Statement of the Problem 
The non-medical use of prescription drugs (NMUPD) is a significant and growing public 
health concern with young adults at great risk for use, abuse, and related negative outcomes (e.g., 
National Institute on Drug Abuse (NIDA), 2011). According to NIDA, NMUPD occurs when 
individuals either use medications that were not prescribed to them, use their prescribed 
medications in higher quantities or manners other than prescribed, or take medications for 
purposes other than prescribed (e.g., to get high; NIDA, 2014). The types of prescription drugs 
used for non-medical purposes most often are stimulants, opioids, and central nervous system 
(CNS) depressants (NIDA, 2011).  
As a population characterized by instability and experimentation, young adults (ages 18-
25) are clearly an at-risk group for substance use (Arnett, 2005). It is during young adulthood 
that, on average, people report initiation of illicit substance use, including NMUPD (Substance 
Abuse and Mental Health Services Administration (SAMHSA), 2013b). Young adults exhibit the 
greatest illicit drug use compared to all other age groups in the United States (SAMHSA, 2013b). 
Additionally, within the twenties is the mean age for onset of NMUPD disorders, and for seeking 
treatment for these disorders (Huang et al., 2006). Further, evidence suggests that adolescent 
decision-making is different than that of young adults, which is different from older adults, as a 
result of brain development (for a reviews see Spear, 2013; Steinberg, 2008). Consequently the 
motivations to engage in NMUPD, and the interventions targeting NMUPD, will likely vary by 
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age. Therefore, this study focuses on the developmental period of young adulthood, the 
population considered most at-risk.  
NMUPD is the second most commonly reported form of illicit substance use by young 
adults, after marijuana (SAMHSA, 2013b). This is a growing public health concern. For example 
in 2014, 884,000 young adults engaged in NMUPD for the first time in the past year (Lipari et 
al., 2015). In full-time college students (ages 18 to 22), NMUPD initiation peaked with an 
average of 850 new users per day for prescription opioids alone in 2013 (Lipari, 2015). More 
people also have been seeking treatment for prescription opioid abuse, with rates for young 
adults increasing by approximately 26% from 2002 to 2010 (SAMHSA, 2011). 
NMUPD has been linked with abuse and dependence (Huang et al., 2006; Hurwitz, 2005; 
Kroutil et al., 2006; SAMHSA, 2013b), and a variety of other negative outcomes in young 
adults, including mental illness (Arria et al., 2008; Bavarian et al., 2013; Janusis & Weyandt, 
2010; Lo et al., 2013; McCauley et al., 2009; McCauley et al., 2010; McCauley et al., 2011; Van 
Eck et al., 2012; Zullig & Divin, 2012), increasing number of emergency room visits (SAMHSA, 
2013a; SAMHSA, 2013b), arrest and delinquency (Drazdowski et al., 2015; Herman-Stahl et al., 
2007), and more unintentional overdose deaths (Paulozzi, 2012). Additionally, young adults who 
engage in NMUPD are significantly more likely than their peers to use other illicit drugs and to 
combine prescription drugs with alcohol and other substances, which increases the risk of 
potentially dangerous drug interactions and their negative outcomes (Garnier et al., 2009; 
McCabe et al., 2006; SAMHSA, 2006). Of particular concern for young adults in collegiate 
settings, many students who endorsed the non-medical use of prescription stimulants and opioids 
also reported spending less time studying, skipping classes more often, earning lower grades 
(Arria et al., 2008), more frequent sexual risk behaviors (Benotsch, Koester, Luckman, Martin, & 
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Cejka, 2011), and more sleep problems (Clegg-Kraynok, McBean, & Montgomery-Downs, 
2011). Clearly NMUPD, particularly by young adults, is a large and growing public health 
problem with significant consequences. Therefore, prevention is key to reducing this public 
health concern and its grave costs to society. 
Unfortunately, the majority of individuals with NMUPD disorders never receive 
treatment for their drug use problems or any mental health issues (Huang et al., 2006). One way 
to prevent substance use is to investigate why specific groups of people use and to target 
interventions specifically to certain predictors. One of these factors, on the individual level, is the 
motivations for why young adults decide to engage in NMUPD. Although it is only one small 
piece of the etiology for drug use and abuse, and needs to be considered along with other factors 
such as molecular genetics, personality patterns, culture, etc. (see Kendler, 2012); motivations 
can be self-reported and are amendable to change (e.g., Miller et al., 1993).  
Different theories exist to explain why individuals are motivated to abuse substances. 
One theory is the self-medication hypothesis initially articulated by Khantzian (1985; 1997) and 
Duncan (1974a; 1974b; 1975). This theory posits that individuals engage in drug abuse to treat 
underlying disorders or problems that have not been properly treated by other means. For others, 
initial use may have started appropriately, such as for pain or for sleep, but then developed into 
addictions based on the properties of the medications themselves (Alam et al., 2012). More 
common in young adults is the theory that individuals ages 18 to 25 are motivated to engage in 
drug use for recreational reasons, partially as the result of the instability and exploration 
encompassing that developmental life stage (Arnett, 2005).  
Previous research supports that motivations for substance use are important predictors of 
use patterns and problems in young adults. For example, drinking motivations predict alcohol 
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consumption and alcohol-related problems in young adults and adolescents (Kuntsche et al., 
2005), as well as mediate or moderate environmental and individual variables with alcohol-
related outcomes in these populations (Cooper et al., 2000; Magid et al., 2007; Kuntsche et al., 
2010; Kenney et al., 2014). Research investigating motivations in young adults supports that 
similar patterns exists for NMUPD. For example, college students who use prescription drugs 
recreationally are more likely to endorse using other drugs, binge drinking, and combining their 
prescription drugs with other substances (Advokat, Guidry, & Martino, 2008; Barrett, Darredeau, 
Bordy, & Pihl, 2005; McCabe, Cranford, Boyd, & Teter, 2007; McCabe, Boyd, & Teter, 2009). 
Although, in at least one study there were no significant differences in lifetime number of drugs 
used between students who used stimulants recreationally versus as a study aid (Barrett et al., 
2005). Additionally, in another study, recreational users also were more likely to report using 
treatment services for substance use compared to users who engaged in NMUPD for self-
treatment reasons. Unfortunately, the frequency for using treatment services was still small 
(10.3%; McCabe et al., 2009). Also, students motivated to use prescription stimulants for 
recreational reasons were more likely to report intranasal use than those using it as a study aid; a 
risk factor for drug abuse (Franke et al., 2011). Clearly, motives are important, not just in how 
they related to NMUPD, but also how they relate to other risk behaviors.  
Since different motivations relate to different patterns of use and outcomes, prevention 
and intervention efforts will likely need to be targeted to most effectively address the 
individual’s needs based on their specific motivations for use. For instance, an individual 
reporting addiction as a motive may need different treatment than an individual reporting 
recreational motives, like to have fun. Additionally, motivations have been recognized by 
SAMHSA as an important treatment target (Center for Substance Abuse Treatment, 2013).  
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The research conducted on the motivations for NMUPD in young adults to date is limited 
in several important ways. The majority of the work has surveyed students in higher education, 
with little work considering how motivations may be similar or different among young adults 
who are not attending college. Additionally, the preponderance of research is about the non-
medical use of prescription stimulants. Very few studies have focused on other commonly 
abused prescription drug classes like prescription opioids and CNS depressants (National 
Institute on Drug Abuse (NIDA), 2011). Further, only one longitudinal study has been conducted 
looking at motivations over time in this population (Garnier-Dykstra, Caldeira, Vincent, 
O'Grady, & Arria, 2012). However, Garnier-Dykstra and colleagues (2012) focused only on 
college students who non-medically used prescription stimulants. McCabe, Schulenberg, 
O'Malley, Patrick, and Kloska (2014) did investigate trends in the non-medical use of 
prescription opioids during young adulthood in a national sample, but did not include 
motivations in the analyses. Without longitudinal work, it is unclear exactly how motivations for 
NMUPD may change over time and if the same motivations continue to influence individuals as 
they progress developmentally.  
Therefore, the current study contributes to the literature on the motivations for NMUPD 
in young adults by addressing some of the limitations of past work. First, the sample consisted of 
a nationally representative sample of high school seniors who have been followed longitudinally 
across three biennial follow-up waves covering ages 19-24 years. With this sample, questions 
about how motivations for NMUPD change over time on the national population level were 
answered. Also, if there are differences over time for motivations for NMUPD of young adults 
who attend college as compared to their peers who do not were investigated, as well as sex 
differences. Further, motivations for new users in the beginning of young adulthood, compared 
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to those who used in high school, as well as changes in NUMPD motivations for new users over 
time were studied. Specific motivations for the non-medical use of prescription stimulants, CNS 
depressants, and opioids were investigated. Thus, expanding the knowledge on less studied 
prescription drug classes. The strengths of the current study move the research on the topic of 
motivations for NMUPD forward. 
Review of the Literature 
Definition and Prevalence of NMUPD in Young Adults 
As noted, NMUPD occurs when individuals either use medications that were not 
prescribed to them, use their prescribed medications in higher quantities or manners other than 
prescribed, or take medications for purposes other than prescribed (e.g., to get high; NIDA, 
2014). Rates of NMUPD vary across prescription drug class and sample. For example, estimates 
from recent nationally representative databases suggest prevalence rates from 3.3% to 4.8% in 
young adults (SAMHSA, 2014). However, studies in U.S. college student samples report ranges 
from 4% to 43% (Advokat et al., 2008; Stone & Merlo, 2011). The types of prescription drugs 
abused most often are stimulants, CNS depressants, and opioids (NIDA, 2011).  
Stimulants are commonly prescribed for Attention-Deficit/Hyperactivity Disorder 
(ADHD), the sleep disorder narcolepsy, and obesity (NIDA, 2011; Yu, 2012). Prescription trends 
suggest that the number of methylphenidate prescriptions (e.g., Concerta, Ritalin) have remained 
relatively stable since 1996 (NIDA, 2011), but the rates of amphetamine prescriptions (e.g., 
Adderall, Dexedrine) have increased (Califano, 2005); with a reported 463% increase between 
1998 and 2007 alone (Belouin, Reuter, Borders-Hemphill, & Mehta, 2008). These medications 
typically are abused because of their ability to increase alertness and attention (Yu, 2012). As 
stimulants tend to increase heart rate and blood pressure, they have been associated with sudden 
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death (Gould et al., 2009). However, it should be noted that two large studies have provided 
evidence that stimulants do not increase the risk of negative cardiovascular events (Cooper et al., 
2011; Habel et al., 2011). That being said, the risk of adverse cardiovascular events still exists 
for individuals in the abuse setting who are taking large dosages (Yu, 2012). Tolerance for these 
medications develops over time, resulting in individuals needing higher doses, or more potent 
drugs to achieve the “high,” similar to other illicit drugs like cocaine and D-amphetamine (i.e., 
“speed”; Rosenfield, Hébert, Stanbrook, Flegel, & MacDonald, 2011). 
CNS depressants often are referred to as tranquilizers or sedatives. They include 
barbiturates, benzodiazepines, and nonbenzodiazepine sleep medications (Yu, 2012). These 
medications commonly are prescribed for anxiety or sleep problems as they slow normal brain 
function. Specifically, barbiturates are used to treat sleep and anxiety disorders (Yu, 2012). 
Benzodiazepines treat anxiety disorders, insomnia, panic disorders, seizures, and muscle 
spasticity (Lalive, Rudolph, Luscher, & Tan, 2011). Nonbenzodiazepines hypnotics, also known 
as “Z-drugs,” are designed to aid sleeping and be less likely to produce tolerance or dependence 
problems (Nutt & Stahl, 2010). Prescribing trends provide evidence that there has been a 
significant reduction in barbiturate prescriptions; however, this is counter-balanced with an 
increase in all other CNS depressant medications (Califano, 2005). These medications are abused 
because of their ability to reduce anxious feelings and inhibitions, similar to the reported 
euphoric effects of alcohol (Yu, 2012). Withdrawal symptoms include insomnia, tremors, 
agitation, anxiety, gastric problems and muscle spasms, which can lead to physical dependence 
(Lalive et al., 2011). The prevalence of lifetime use of CNS depressants among young adults for 
benzodiazepines only was estimated to be about 13% in 2013 (Johnston, O’Malley, Bachman, 
Schulenberg, & Miech, 2014).  
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Opioids are prescribed primarily for pain relief (U.S. Food and Drug Administration, 
2014). These medications also can be prescribed as antitussive or antidiarrheal agents (Yu, 
2012). Trends in prescribing suggest that opioids are being used increasingly to treat chronic 
pain, acute and postsurgical pain, as well as for palliative care (Manchikanti, Fellows, Ailinani, 
& Pampati, 2010). This trend is the most noticeable in the U.S., as the U.S. alone consumes 
around 80% of the world’s supply of opioids even though residents only make up 4.6% of the 
world’s population (Manchikanti et al., 2010). Prescription opioids are commonly abused 
because of their ability to induce a feeling of euphoria. Abuse of prescription opioids also leads 
to tolerance for these medications (NIDA, 2011). Undesirable withdrawal symptoms, such as 
sleep problems, anxiety, chills, runny nose, sweating, muscle twitching, muscle aches, and 
agitation, also encourage users to continue to use these medications (SAMHSA, 2013c). Among 
young adults, the prevalence of the non-medical use of prescription opioids has remained 
relatively stable since 2002, with a recent decline according to the National Survey on Drug Use 
and Health (NSDUH), ranging from 20.8% (2013) to 25.5% (2005-06). A similar trend was 
reported in the Monitoring the Future (MTF) study, with prevalence rates for young adults 
ranging from 14.5% (2013) to 17.9% (2006; SAMHSA, 2014). 
Rates of overall NMUPD are rising and young adults are at more risk than other age 
group. For example, in 2010 there was an average of 6,600 new NMUPD initiates per day 
(SAMHSA, 2013b). There were approximately 1.4 million new users of tranquilizers and 
sedatives. From 2002 to 2010, the rate of just opioid dependence increased from 0.4% to 0.6% of 
the population, resulting in an increase from 936,000 to 1,400,000 people with about one third 
aged 18 to 25 (SAMHSA, 2011). More people have also been seeking treatment for opioid 
abuse; with the rates for young adults increasing by approximately 26% from 2002 to 2010. 
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Additionally, the early 20s is the mean age for onset of NMUPD disorders across types of 
prescription medication, and the mid-20s is the mean age for seeking treatment for NMUPD 
disorders (Huang et al., 2006). Therefore, young adults are an important population to target for 
prevention and intervention.  
There are a variety of reasons for why NMUPD is becoming more common, especially 
with young adult populations. First, there has been an increase in retail sales of prescription 
medications that has led to more availability (Yu, 2012). Specifically, between 1997 and 2007, 
the retail sales of opioids more than doubled, with 126.5 million grams sold in 2007 
(Manchikanti et al., 2010). From 1991 to 2010, the total number of opioid prescriptions increased 
from 76 million to 210 million (NIDA, 2011). Another factor implicated in the increasing rates 
of NMUPD is the perception that because they are prescribed, and thus approved by Federal 
Drug Administration (FDA), they are “safer” than other drugs. Many studies have found that 
young adults believe this to be true (Arria, Caldeira, Vincent, O'Grady, & Wish, 2008; DeSantis, 
Webb, & Noar, 2008; Fleary, Heffer, & McKyer, 2013; Inciardi, Surratt, Kurtz, & Cicero, 2007; 
Mui, Sales, & Murphy, 2014). Prescription drugs, like prescription opioids, also are perceived as 
less stigmatizing and less illegal when compared to other illicit drugs like heroin (Inciardi et al., 
2009). Further, young adults also appear to not be knowledgeable about the illegality of giving or 
taking prescription drugs without a doctor’s permission (DeSantis et al., 2008). For these 
reasons, it is important to further investigate NMUPD users in this developmental period. 
Negative Behaviors and Outcomes Associated with NMUPD in Young Adults 
Every prescription medication comes with warnings of potential adverse side effects. 
Individuals engaging in NMUPD are putting themselves at-risk for experiencing these negative 
effects. For instance, if one takes too many prescription opioids he/she may experience loss of 
     
10 
 
muscle tone, confusion, slowness of heart rate, stupor, respiratory depression, coma, and even 
sudden death (SAMHSA, 2013c); while overdoses of stimulants can result in seizures, feelings 
of paranoia, respiratory failure, or cardiac arrest. Other adverse effects of stimulants include 
headache, palpitations, hypertension, arrhythmias, depression, agitation and aggressiveness 
(NIDA, 2011). CNS depressant abuse can produce disinhibitory and aggressive effects that result 
in violence and assault (Lader, 2011). The risk of experiencing these adverse effects is increased 
when prescription drugs are combined or used in combination with other drugs or alcohol. If 
CNS depressants are used with alcohol and opioids, the aforementioned problems are more 
severe and common (Jann, Kennedy, & Lopez, 2014; Lader, 2011). In another example, CNS 
depressants and alcohol are commonly also found in opioid-related deaths in the United States 
(Webster et al., 2011). Also, individuals who engage in NMUPD have reported medical 
problems such as cardiac arrhythmias and respiratory depression (Nissen, 2006), as well as 
cognitive deficits (Barker, Greenwood, Jackson, & Crowe, 2004; Barker, Greenwood, Jackson, 
& Crowe, 2004). 
Further, medical emergencies related to NMUPD have increased 132% from 2004 to 
2011 (SAMHSA, 2013b). Over 1.2 million emergency department (ED) visits involved the non-
medical use of prescription medicines, over-the-counter drugs, or other types of pharmaceuticals 
in 2011, accounting for 51% of all ED visits involving illicit substances (SAMHSA, 2013a; 
Paulozzi, 2012). Since 2004, rates of suicide cases that involve some type of CNS depressant 
have increased between 105% and 148% depending on type of medication (SAMHSA, 2013a). 
NMUPD also is involved in the rising numbers of unintentional overdose deaths. From 1999 to 
2000, unintentional overdose deaths involving opioid pain relievers alone have quadrupled, and 
by 2007 they outnumbered those involving heroin and cocaine combined (Paulozzi, 2012).  
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NMUPD also leads to abuse and dependence (Huang et al., 2006; Hurwitz, 2005; Kroutil 
et al., 2006; SAMHSA, 2013b) and potentially may be “gateway” drugs for other illicit 
substances. Approximately, 54,000 young adults met criteria for NMUPD abuse or dependence 
in 2012 (SAMHSA, 2013b), with individuals reporting the most abuse and dependence for 
stimulants in the United States, specifically amphetamines (Huang et al., 2006). In samples from 
a variety of studies of individuals who inject heroin, 24%-86% reported the misuse of 
prescription opioids first, suggesting that NMUPD may be a risk factor for future drug use 
(Brands, Blake, Sproule, Gourlay, & Busto, 2004; Cicero, Ellis, Surratt, & Kurtz, 2014; Cicero, 
Ellis, & Surratt, 2012; Grau et al., 2007; Lankenau et al., 2012; Peavy et al., 2012; Pollini et al., 
2011). 
Young adults who report NMUPD also report more cigarette smoking, heavy episodic 
drinking, marijuana use, cocaine use, hallucinogen use, inhalant use, and use of other illicit 
substances (Garnier et al., 2009; McCabe et al., 2006; SAMHSA, 2006). These combinations can 
increase their risks of negative outcomes. Indeed, more than half of ED visits for prescription 
drug abuse involve multiple drugs and approximately 20% also involve alcohol (SAMHSA, 
2013b). Further, NMUPD drug use disorders are associated with many other Axis I and II 
disorders (Huang et al., 2006). This comorbidity between mental health problems and substance 
use puts NMUPD users at even greater risk for negative outcomes. For instance, individuals with 
comorbid mental health symptoms who engage in NMUPD are at increased risk of NMUPD 
overdoses (Braden et al., 2010; Porucznik, Johnson, Sauer, Crook, & Rolfs, 2011). 
Within the general community, NMUPD has become a public safety threat, with 
increases in property and violent crime associated with prescription drug diversion (Inciardi et 
al., 2007). NMUPD is a predictor for an increased risk of future delinquency in youth already 
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involved in the justice system (Drazdowski, Jäggi, Borre, & Kliewer, 2015), although other 
known risk factors (e.g., previous delinquency, violence exposure) put youth more at risk than 
NMUPD alone. Young adults specifically, from a national sample, also have increased arrest 
rates if they report the non-medical use of prescription stimulants (Herman-Stahl, Krebs, Kroutil, 
& Heller, 2007). 
Of particular concern for young adults in collegiate settings, many students who endorse 
the non-medical use of prescription stimulants and opioids spent less time studying, skipped 
classes more often, and earned lower grades (Arria et al., 2008). Additionally, NMUPD has been 
associated with more frequent sexual risk behaviors in college students (Benotsch, Koester, 
Luckman, Martin, & Cejka, 2011). They also report more sleep problems (Clegg-Kraynok, 
McBean, & Montgomery-Downs, 2011). Further, depression has been associated with NMUPD 
in college students (Bavarian, Flay, & Smit, 2014; McCauley et al., 2011; Zullig & Divin, 2012). 
Similar results have been found for the relation between ADHD symptoms and the non-medical 
use of prescription stimulants in college students (Arria et al., 2011; Janusis & Weyandt, 2010; 
Van Eck et al., 2012). There is a wealth of evidence that NMUPD, particularly by young adults, 
is a large and growing public health problem with significant consequences. 
Developmental Stage of Young Adulthood 
 The international chronological age for defining adulthood is 18 years old (Cohen, 
Stromquist, Behrman, & Lloyd, 2006). However, in today’s society in the United States the 
traditional transitional markers that have defined adulthood, such as marriage and having 
children, are no longer the most prominent markers characterizing young adults (e.g., Settersten, 
Furstenberg, & Rumbaut, 2005). Scholars are recognizing that there is a separate developmental 
period between adolescence and adulthood. This new transitional time in development is 
     
13 
 
occurring across cultures in industrialized nations. For example, in Japan, “freeters” are 
individuals aged 15 to 34 who typically are working part-time, temporary positions and are not 
enrolled in higher education (Newman, 2008). In the United States the popular press has referred 
to individuals in this developmental stage as “twixters” (Grossman, 2005), or used the term 
“adultscence” (Gordon & Shaffer, 2004). These terms highlight a more recently recognized in-
between developmental stage of young adulthood where more self-exploration occurs after 
adolescence and the stability and maturity of adulthood is not yet achieved. During this period 
some of the following social role transitions are expected to occur: leaving home, gaining 
financial independence, gaining independence in decision making, making a partnership 
commitment, renegotiating relationships with parents, starting a career, becoming a parent, 
engaging with the community and the wider social world (Hutchison, 2015).  
 More research has been conducted about the development of the brain during this life 
stage and have found that brain development does not cease in adolescence (see Casey & Jones, 
2010; Crews, He, & Hodge, 2007; Gladwin, Figner, Crone, & Wiers, 2011; Spear, 2013; 
Steinberg, 2008 for reviews). Rather, researchers have found that in young adulthood the brain is 
still developing and a neurologic pruning process occurs which leads to more focused and 
efficient processing in the later adult years. Gray and white matter continue to increase into the 
early 20s. Additionally, brain areas responsible for emotions (e.g., amygdala) become fully 
developed by mid-adolescence while the frontal lobes are still in development. Research has now 
found evidence that the frontal lobes do not reach maturity until approximately age 25. As the 
frontal lobes are responsible for long-term thinking, it is more common to see emotion-driven 
decision-making as compared to methodical decision-making during this stage. Accordingly, 
there are increases in risk-taking with young adults being less likely to regard possible 
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consequences. Further, there is an increased susceptibility during this stage to the rewarding 
properties of substances as compared to older adults.  
Which biological ages define young adulthood is debated by developmental 
psychologists and scholars. For example, suggested age ranges have included 17 to 45 
(Levinson, 1986), 18 to 34 (Settersten et al., 2005), and 22 to 34 (Ashford & LeCroy, 2010). 
However, some theorists have found these age ranges too broadly defined. Specifically, Arnett 
(2000) states, “It makes little sense to lump late teens, twenties, and thirties together and call the 
entire period young adulthood. The period from ages 18 to 25 could hardly be more distinct from 
the thirties.” (p. 479).  
 Theory of emerging adulthood. Jeffery Arnett has specifically defined the term 
“emerging adulthood,” to capture the distinct development stage between adolescence and 
adulthood that occurs between ages 18 to 25 in industrialized societies (Arnett, 2000). This age 
stage is based on research suggesting that the majority of young adults ages 18 to 25 do not 
believe that they have reached adulthood yet; but by age 30 most people believe they have 
reached adulthood. The central focus of emerging adulthood is a prolonged identity exploration 
(Arnett, 2007; Arnett, 2006). Specifically, during this stage young adults are exploring social and 
economic roles by experimenting with new experiences related to love, work, financial 
responsibilities, and educational interests, without committing to a particular long-term plan. 
Arnett conceptualizes this as a period of unstructured time where emerging adults are not yet 
attached to social institutions (Arnett, 2007). For instance, young adults in this stage are moving 
out from their families of origin and have not formed new families of their own yet. The mid-20s 
is when residential instability and mobility are typically at their highest (Rindfuss, Cooksey, & 
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Sutterlin, 1999). Additionally, many are moving out from prior educational systems into new 
educational or employment sectors.  
As a result of all these changes, this developmental period is marked by experimentation 
and instability. Therefore, it is not surprising that it also is during the ages of 18 to 25 that we 
find the most reported illicit drug use (SAMHSA, 2013b). Further, between the ages of 18 to 25 
are when many individuals are at-risk for developing mental health disorders. Beyond being at 
the most risk for NMUPD abuse and dependence (Huang et al., 2006), young adults also are at-
risk for the onset of many other disorders such as depression, generalized anxiety, schizophrenia, 
and bi-polar disorder to name a few (Kessler et al., 2005).  
Theories of Motivations for Substance Abuse in Young Adults 
 There are many theoretical frameworks for the motivations behind initial drug use and 
continuing drug abuse. One theory for why individuals are motivated to use and abuse drugs is 
the psychodynamic and behaviorally self-medication hypothesis initially articulated by 
Khantzian (1985; 1997) and Duncan (1974a; 1974b; 1975). This theory posits that individuals 
engage in drug abuse to treat underlying disorders or problems that have not been properly 
treated by other means. Self-medication occurs because individuals self-diagnosis their 
symptoms or problems and seek means to alleviate these symptoms. As a result, individuals 
chose to use or abuse certain substances based on their specific symptoms. For example, an 
individual who has self-diagnosed attention problems may self-medicate with prescription 
stimulants, while a person with anxiety and sleep problems would instead self-medicate with 
CNS depressants. Further, this theory highlights the negative reinforcement experienced by drug 
users. Users who self-medicate are motivated to reduce their symptoms and negative affect, as 
well as to avoid withdrawal symptoms. These experiences reinforce future use of drugs. This 
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theory is supported by findings that one factor that differentiates recreational users from 
problematic users is the presence of negative reinforcement. If the presence of negative 
reinforcement is reported, individuals are more likely to be problematic users (Nicholson, 
Duncan, & White, 2002). The self-medication hypothesis would support motivations where 
individuals are using prescription drugs non-medically as they were intended (e.g., stimulants to 
improve concentration). Additionally, this theory would support motivations that suggest 
escaping stressors and problems (e.g., to get away from my problems or troubles). 
 However, the self-medication hypothesis does not appear to account for all young adults 
who use prescription drugs non-medically. For others, initial prescription drug use may have 
started appropriately, such as with a prescription for pain or for sleep from a doctor, but then 
developed into addictions based on the properties of the medications themselves. For example, 
studies have shown that patients are more likely to become long-term opioid users if they were 
prescribed with an opioid within seven days of surgery, compared with those who received no 
opioid prescription (Alam et al., 2012). As all of the prescription drugs that are commonly 
abused have some addictive properties with the development of tolerance and associated 
withdrawal symptoms, as noted earlier, this theory of substance use and abuse also may be 
occurring and needs to be considered as a potential motivation (e.g., because I am “hooked”—I 
feel I have to have them). 
 Additionally, more common in young adults is the theory that individuals ages 18 to 25 
engage in more drug use for recreational reasons as part of the self-exploration process and 
instability experienced during this this developmental period (Arnett, 2005). Specifically Arnett 
(2005) suggests that emerging adults use substances because they are curious about the 
experiences of using various substances and want to have a wide range of experiences before 
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they settle into adult life. Also, since constructing a stable identity may be confusing and 
difficult, emerging adults may use substances to relieve these negative feelings stemming from 
identity confusion. Further, as emerging adulthood is a time of instability; young adults may be 
more likely to use substances because of the stress and negative affect that are associated with 
disruptions in life (e.g., new residences, romantic partners, educational and vocational settings). 
Young adults also have the ability to make more independent decisions, and are 
frequently transitioning out of their parents’ house which may lead to engaging in more deviant 
behaviors including substance use. Substance use also may be explained by the feeling of in-
between experienced by many young adults; that they are no longer adolescents but not yet 
adults. Therefore, young adults have the ability to make independent choices about substance use 
that their caregivers previously had decided against, however, they do not yet feel the need to be 
as responsible in their drug use as they believe adults should act. This part of Arnett’s theory also 
is supported by research on brain development suggesting that young adults do not yet have the 
cognitive capacity to make methodical decisions over emotion-driven decisions (e.g., Steinberg, 
2008).  
Finally, Arnett (2005) proposes that emerging adulthood sets individuals up for believing 
that they have the opportunity to make dramatic changes in their lives and optimism is very 
common. As a result of this optimism people in this developmental stage may not fully consider 
the negative consequences that may result from substance use. All of these potential explanations 
may relate to different motivations to engage in NMUPD, especially recreational motives (e.g., 
to experiment—to see what it’s like, to feel good or get high, to seek deeper insights and 
understanding, to have a good time with my friends, to fit in with a group I like, because of 
boredom/nothing else to do, etc.). 
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 For the purposes of this study the focus point for prevention and intervention will be on 
the individual level and one’s reported motives to use. Although it is only one small piece of the 
etiology for drug abuse and needs to be considered along with other factors such as molecular 
genetics, personality patterns, culture, etc. (see Kendler, 2012), motivations are a factor that can 
be self-reported and are amendable to change (e.g., Miller, Benefield, & Tonigan, 1993). Since 
different motivations relate to different theories of drug abuse, prevention and intervention 
efforts will likely need to be targeted to most effectively address the individual’s needs based on 
their specific motivations for use. For instance, an individual reporting addiction as a motive may 
need different treatment than an individual reporting recreational motives. Motivations have been 
recognized by SAMHSA as an importance treatment target. This is highlighted in their 
publication, “Enhancing Motivation for Change in Substance Abuse Treatment,” a 260-page 
document that is part of their Treatment Improvement Protocol (TIP) Series (Center for 
Substance Abuse Treatment, 2013).  
Furthermore, given the theory of instability in this life stage (Arnett, 2005), there may be 
changes in the patterns of motivations reported by young adults across this period. Research is 
needed on this topic to help determine where to target interventions to make them 
developmentally appropriate. Hopefully research in this area will help reduce the findings that 
the majority of individuals with NMUPD disorders never received treatment for their drug use 
problems or any mental health issues (Huang et al., 2006). 
Research on Motivations for NMUPD in Young Adults 
With the high rates of use and the associated negative outcomes from use, research on the 
motivations for NMUPD in young adults has been a burgeoning area. The following section 
describes the research on motivations for NMUPD in exclusively young adults to date. The 
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description of the studies is organized by class of prescription medication investigated as defined 
by NIDA: stimulants, opioids, and CNS depressants so summaries of the general trends in 
motivations can be described. Then, research that included young adults not currently enrolled in 
college will be discussed to address any differences found in this population. If sex differences 
have been reported in any studies they also are presented. Finally, results that include work 
outside of the United States, but still conducted in industrialized nations, will be reviewed as a 
comparison for motives across cultures. After reviewing the results of the separate drug classes 
research that has investigated motives across drug classes (i.e., NMUPD in general) will be 
discussed to acknowledge general trends in NMUPD. 
Overall, the majority of the studies investigated the motivations to use stimulants non-
medically; followed by studies investigating prescription opioids and CNS depressants, 
respectively, either as a separate study or along with investigating the motives for the non-
medical use of stimulant mediations. Across class of prescription medication, the majority of the 
research was conducted in the United States with college students and was cross-sectional. 
Motivations for the non-medical use of stimulants. Thirty-five studies have 
investigated the motivations for the non-medical use of prescription stimulants in young adult 
populations exclusively. Of these articles, 31 were conducted in the United States and four were 
conducted outside of the United States. Additionally, all articles included college student 
samples, while two included other young adult populations. Sample sizes ranged from 50 to 
9,161 young adults.  
Stimulant motivation results in United States samples. Overall, in all but three studies, 
the common motivations for stimulant non-medical use were to use the medications for academic 
reasons and for reason the medications are clinically prescribed (e.g., to improve concentration; 
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Advokat et al., 2008; Barrett et al., 2005; Bavarian et al., 2013; Clegg-Kraynok et al., 2011; 
DeSantis et al., 2008; Dupont, Coleman, Bucher, & Wilford, 2008; Dussault & Weyandt, 2013; 
Franke et al., 2011; Gallucci, Usdan, Martin, & Bolland, 2014; Garnier-Dykstra et al., 2012; 
Ghandour, El Sayed, & Martins, 2012; Hall, Irwin, Bowman, Frankenberger, & Jewett, 2005; 
Hartung et al., 2013; Herman et al., 2011; Holloway & Bennett, 2012; Judson & Langdon, 2009; 
Lookatch, Dunne, & Katz, 2012; Lord et al., 2009; Low & Gendaszek, 2002; McCabe et al., 
2009; McNiel et al., 2011; Peterkin, Crone, Sheridan, & Wise, 2011; Prudhomme White, Becker-
Blease, & Grace-Bishop, 2006; Rabiner, Anastopoulos, Costello, Hoyle, McCabe, & 
Swartzwelder, 2009a; Rabiner, Anastopoulos, Costello, Hoyle, McCabe, & Swartzwelder, 
2009b; Rozenbroek & Rothstein, 2011; Rozenbroek & Rothstein, 2011; Stone & Merlo, 2011; 
Teter, McCabe, Cranford, Boyd, & Guthrie, 2005; Teter, McCabe, LaGrange, Cranford, & Boyd, 
2006; Tuttle, Scheurich, & Ranseen, 2010; Upadhyay et al., 2010; Weyandt et al., 2009). 
Even though the main motivations were to use prescription stimulants for academic 
reasons or for the drugs prescribed effects, recreational motives also were common. For example, 
across studies the motivation to get high was reported in 2% to 43% when it was recorded in the 
sample (Gallucci et al., 2014; Teter et al., 2005). Additionally, there were some unique 
motivations that were mentioned. These included, “I ran out of my own prescription” (Gallucci 
et al., 2014), “prevent the academic advantage of others” (Gallucci et al., 2014), 
aphrodisiac/enhance sexual performance (Lookatch et al., 2012; Lord, Brevard, & Budman, 
2011), increase energy to exercise/enhance athletic performance (Judson & Langdon, 2009; 
Lookatch et al., 2012; Low & Gendaszek, 2002), “makes me feel more confident and social” 
(Clegg-Kraynok et al., 2011) and “safer than street drugs” (Ghandour et al., 2012; McCabe et al., 
2007). 
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Other trends in stimulant motivation results. There were three studies that listed non-
academic motivations. However, all of these studies focused only on specific motivations not 
related to stimulant medications intended uses. For example, Upadhyaya and colleagues (2005) 
investigated 334 college students at one university who used prescription stimulants non-
medically to get high, which occurred in 25% of students who reported having a prescription for 
stimulants. The other two studies focused on the motivation to use stimulant medications non-
medically for weight loss, with prevalence rates of this motivation ranging from 4% to 12% in 
two samples of approximately 700 undergraduate students at the same university (Jeffers, 
Benotsch, & Koester, 2013; Jeffers & Benotsch, 2014). No sex differences were reported. In the 
one sample, the authors found that weight loss motivation was related to a variety of other 
problems including more body image concerns, more use of illicit drugs, more eating disorder 
symptoms, including using vomiting and other pills (e.g., laxatives, diet pills) for weight control 
(Jeffers & Benotsch, 2014). All of these studies are limited by the fact that they only assessed 
one potential motivation for NMUPD and only investigated students at one university per 
sample. Additionally, all were cross-sectional. 
Evidence that motivations change over time in young adulthood. The most 
comprehensive study of motivations across this developmental period was conducted by Garnier-
Dykstra and colleagues (2012). In the only longitudinal study, the authors investigated the non-
medical use of prescription stimulants across four years in a sample of 1,253 undergraduate 
students in a large, public university in the mid-Atlantic region (ages 17-19 years) with in-person 
interviews. Motivations were assessed by recording the participants’ verbatim responses to the 
question, “What were the reasons you had for using <prescription stimulant>?” Answers were 
then coded into one of five categories. The results found that across all time points, using 
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prescription stimulants to “improve focus/study/work” remained the most reported motive for 
non-medical use and increased over time. Additionally, curiosity/experimentation motivations 
significantly decreased over time. There were no significant changes in the following motives: to 
get high, to stay awake to party, and other. However, it should be noted that this study only 
included students at one university.  
Studies including young adults not in higher education. The only study that did not 
exclusively investigate a student population in the United States found that motivations to use 
stimulants non-medically in young adults are similar to those in college. In a sample of 3,307 
young adults (ages 18 to 25) recruited from the Harris Poll Online panel, the most frequently 
reported motive was, “to be more productive” (Upadhyaya et al., 2010). Across different 
formulas of stimulant medications, young adults also reported using stimulants non-medically for 
recreational reasons (22%-43%). These results highlight that recreational motives for use are 
important in the young adult population in general as well, and not just for young adults in 
collegiate settings. Additionally, there may not be many differences for why individuals are 
motivated to engage in NMUPD based on whether they attend college or not. Unfortunately 
differences in motivations based on whether individuals were enrolled in college or not was not 
tested in this study. Therefore, definitive conclusions about the lack or presence of differences in 
motivations between these populations cannot be made.   
Stimulant motivation results in non-American samples. In studies conducted outside the 
United States, Barrett and colleagues (2005) surveyed the motives of 50 Canadian students who 
solely reported the non-medical use of stimulant medication methylphenidate. The results 
indicated that out of the two options provided, most students (70%) categorized their non-
medical use as recreational, while the rest reported using methylphenidate as a study aid. The co-
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occurrence of these motives was not assessed. Franke and colleagues (2011) sampled 1,547 
pupils (i.e., students in grammar school, public vocational schools, or young adults preparing for 
university or obtaining a job) and university students in Germany. However, the only motivation 
assessed was using stimulant medications for solely cognitive enhancement purposes. Overall, 
rates were low in the sample (0.1-1.3% over time), with males reporting more non-medical use 
of prescription stimulants for cognitive enhancement as compared to females for pupils. No sex 
differences were found in the university student sample. Ghandour  and colleagues (2012) 
assessed the non-medical motives of 570 Lebanese students, and found that most university 
students sampled reported using stimulant medications for their prescribed purposes and for 
academic reasons (e.g., to concentrate, increase alertness, help study). Unlike most of the other 
studies, but similar to the results of Canadian students (Barrett et al., 2005), a sample of 1,517 
undergraduate and postgraduate students in the United Kingdom reported using stimulants non-
medically mostly for pleasure, to lose weight, or “to play sport,” with academic motives for use 
being the least endorsed (Holloway & Bennett, 2012). 
Summary. Based on the large amount of research conducted to date in different 
universities it can be concluded that most young adults in collegiate settings are motivated to use 
prescription stimulants non-medically to experience the intended effects of stimulant 
medications. Additionally, it appears that recreational motives also are common, though 
prevalence rates are more varied across samples. Further, conclusions about the motivations to 
engage in the non-medical use of prescription stimulants for young adults not attending college is 
questionable given that only two studies have included participants from this population, and the 
two studies were from different countries, making conclusions based on similarities or 
differences difficult as culture may account for some of the differences. There do appear to be 
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differences in motivations based on country, with some young adults outside of the United States 
reporting more recreational motives. Given the limited studies conducted outside of the United 
States this conclusion should be made with caution.    
Motivations for the non-medical use of opioids. Seven studies have investigated the 
motivations for the non-medical use of prescription opioids in entirely young adult samples. Of 
these articles, five were conducted in the United States, two out of the United States, and all were 
in college student samples. Relieving pain was a popularly reported motivation, although it was 
not consistently the most frequently reported motivation. Relieving pain was typically followed 
by reports of more recreational motives like to have fun, get high, and curiosity. 
Opioid motivation results in United States samples. Lord and colleagues (2011) focused 
solely on the motivations for the misuse of opioid prescriptions in a sample of 527 American 
collegiate students in four-year institutions using the social media site Facebook to recruit 
participants. The authors found that the most common motivations were not necessarily related 
to the intended uses of the medication, as most students reported using prescription opioids to 
relax, followed by have fun. Only 19% of students reported using prescription opioids to manage 
chronic pain, and improving sleep was not listed as a motive in the initial checklist, but was 
provided by at least one participant in the additional write in category. When sex differences of 
motivations were investigated, males were more likely to report using opioid prescriptions for 
the non-medical uses of getting high and having fun as compared to females. Females on the 
other hand were more likely to report being motivated to misuse opioids to cope with depression 
or anxiety, to help with chronic pain, and to manage weight. Finally, students who had begun 
misusing prescription opioids before college reported the motives “to get high” and “to have fun” 
more frequently than those students who began misusing in college. A methodological strength 
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of this study was that included students from a variety of colleges. However, as compared to 
other research the smaller sample size suggests that selection bias may be more prominent in this 
sample compared to others, especially because no incentive was offered for participation in the 
study.  
Some of the same authors investigated motives using similar questions in a subset of 
young adults; 950 PharmD students in a college of pharmacy in the United States training to 
become pharmacists (Lord et al., 2009). The results suggested that similar to the findings of 
American college students in general, students primarily used prescription opioids non-medically 
to have fun and relax. Although in this sample, more students did report using prescription 
opioids to manage chronic pain (23%). Further, the motivation to improve sleep was specifically 
queried in this study with 20% of the sample reporting using opioids for this purpose. In regards 
to sex differences, men were more likely to use opioids non-medically to get high.  
McCabe and colleagues (2009) investigated motivations for opioid use as well and found 
within their lifetime most undergraduates from their sample of 3,639 students attending a large 
public research university used prescription opioids for self-treatment motives only. This was 
followed by a combination of self-treatment and recreation motives (mixed subtype) and then 
recreational only motives. However, there was a slightly different pattern for past year 
prescription opioid non-medical use. For participants reporting past year non-medical use, more 
students reporting mixed motivations (self-treatment and recreational), followed by self-
treatment only motives, with the least number of students endorsing recreational only motives 
again. There were sex differences in motivational subtypes. More females reported self-treatment 
motives for prescription opioids, while males endorsed more recreational and mixed motivation 
subtypes. Further, students from the recreational subtype were more likely to endorse binge 
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drinking, alcohol abuse, other illicit drug use, and drug abuse. However, more students from the 
recreational subtype also reported using treatment services for substance use the most of all 
subtypes, although the frequency was still low (10.3%). It is important to note that students in the 
self-treatment subtype did not significantly differ than students who endorsed no non-medical 
use of prescription opioids on these measures. 
Within the same sample, research that focused more specifically on the motivations for 
the non-medical use of prescription opioids was conducted analyzing the responses from 4,580 
undergraduate students completing the online survey (McCabe et al., 2007). The main 
motivation reported was to use the drug non-medically as clinically intended, to relieve pain. The 
next two most common motives were: to get high and because of experimentation. To help with 
sleep was the fourth most common motive reported. Type of motivation was found to be 
important in relation to other substance use and substance-related problems, such that students 
who reported motivations other than to relieve pain were more likely to report binge drinking, 
alcohol problems, using illicit drugs, and experiencing more drug use related problems, 
compared to non-medical users using for pain relief and non-users. Students who reported 
misusing prescription opioids for pain were more likely than non-users to endorse using 
marijuana or other illicit drugs only; no other substance abuse behaviors were significantly 
different. The authors again found sex differences for some motivations. Males were more likely 
than females to report using prescription opioids to get high, for experimentation, because they 
believed they were safer than street drugs, and to counteract the effects of other drugs. There 
were no sex differences for the motivations of pain relief, to help sleep, and to decrease anxiety. 
Using a smaller sample, Rozenbroek and Rothstein (2011) assessed the motivations for 
the non-medical use of prescription opioids of 413 undergraduate college students using an in 
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class survey. The authors found that most students reported using the medications to “feel good,” 
followed by curiosity, and other motivations. No participants reported using them to improve 
their sleep. Unfortunately, the motive to help manage pain was not directly assessed, a prominent 
weakness in this study.  
Opioid motivation results in non-American samples. The research study conducted in 
Lebanon also investigated the motivations for prescription opioid non-medical use (Ghandour et 
al., 2012), which was the most commonly reported prescription drug used non-medically in the 
sample. The main motives reported included using the drug as it was clinically intended (i.e., 
relieves pain, helps sleep), followed by decreasing anxiety and experimentation. The study 
conducted in the United Kingdom found similar results, with an overwhelming majority of 
students being motivated to use prescription opioids non-medically to relieve pain (Holloway & 
Bennett, 2012), although sleep was not assessed. Opioids also were the most commonly reported 
prescription drug used non-medically in this sample as well.  
Summary. Strong conclusions about the motivations for the non-medical use of 
prescription opioids is difficult to determine at this time given the limited amount of research 
conducted thus far. Further, two of the studies with the largest sample sizes came from the same 
sample of undergraduate students limiting the generalizability of their findings. The results 
therefore are equivocal for whether young adults are motivated to use prescription opioids non-
medical to treat pain or for more recreational purposes in the United States, especially 
considering that not all of the studies assessed pain relief as a possible motivation for use. 
However, there is an emerging trend that more college students in the United States use 
prescription opioids recreationally as compared to students in other countries. Further, as no 
studies included young adults not attending college the motivations for the non-medical use of 
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prescription opioids in this population is yet to be determined. On the other hand, there were 
consistent sex differences noted, primarily that men were more likely to report using prescription 
opioids non-medically for recreational reasons compared to women.  
Motivations for the non-medical use of CNS depressants. Five studies have 
investigated the motivations for the non-medical use of prescription CNS depressants in young 
adult populations along with the other prescription medications described above. Of these 
articles, three were conducted in the United States, two outside of the United States, and all were 
in student samples. In three studies to use the drugs as clinically intended (e.g., to sleep, to 
relieve anxiety) was the most reported motivation. While in one study the general motive “makes 
me feel good” was most commonly reported (Rozenbroek & Rothstein, 2011) and to get high 
was the most reported in another (Stone & Merlo, 2011). Across studies to get high and curiosity 
motives were the next most frequently reported motivations.  
CNS depressant motivation results in United States samples. One study of 413 
American college students investigated CNS depressants as a whole group of medications. Using 
an in-class survey researchers found that the majority of students used CNS depressants to feel 
good, followed by curiosity, and then to perform better at school (Rozenbroek & Rothstein, 
2011). Stone and Merlo (2011) on the other hand focused on benzodiazepines specifically. In 
their sample of 383 mainly undergraduate university students most used benzodiazepines 
specifically to get high or “party,” followed by to relax or “zone out.” A large number of 
students also endorsed “other” reasons which were not detailed in the study. Both of these 
studies had small samples of the total college student population (approximately 12,000 to 
32,000 students, respectively), suggesting that selection bias may have occurred in these studies. 
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McCabe and colleagues (2009), discussed above, divided CNS depressants into sleeping 
and sedative/anxiety medications. Within the motivation subtypes, most students reported using 
sleeping medications for self-treatment only, across lifetime and past-year use. Though there 
were differences in prevalence rates based on sex for motivational subtypes for sleeping 
medication the differences were small (i.e., largest difference for self-treatment subtype, 2.9% 
female:2.1% male). For sedatives/anxiety medications and both lifetime and past-year use, the 
most popular subtype was recreational only, followed by the mixed subtype, with the least 
amount of students endorsing the self-treatment only subtype. The differences in motivation 
subtype based on sex were more prominent, with more females categorized in the self-treatment 
only subtype, and more males in the recreational only and mixed subtype.  
CNS depressant motivation results in non-American samples. Two studies investigated 
the non-medical use of CNS depressants in samples outside of the United States. Along with the 
other prescription medications described above, Ghandour and colleagues (2012) researched the 
motivations for CNS depressants in Lebanese students. These authors categorized anxiety and 
sleeping medications separately. In line with their other results, the authors found that students 
from their sample were motivated to use both sleeping and anxiety medications primarily for 
their clinically intended purposes, though there were still many students who endorsed using 
CNS depressants for other reasons like to get high or counteract the effects of other drugs. In the 
sample of university students from the United Kingdom, a similar categorization of CNS 
depressants was made, but the two categories were labeled sleeping aids and sedatives 
(Holloway & Bennett, 2012). The main motives for non-medical use also were to use the 
medications as clinically intended, but the second most commonly reported reason for both was 
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to get high. However, this motive was much less frequently endorsed for sleeping aids (6%) as 
compared to sedatives (27%). 
Summary. Similar to the work on prescription opioids, positive assumptions about the 
motivations for the non-medical use of prescription CNS depressants is difficult to determine 
given the limited literature on this topic to date. However, there is an emerging trend that CNS 
depressants used for sleeping may be more likely to be used as clinically intended compared to 
sedative and anxiety medications. Again, as no research was conducted on non-student 
populations the motives for these young adults to use is not currently known. In terms of sex 
differences, there is emerging evidence that females may be more likely to use CNS depressants 
non-medically for reasons they are prescribed, while males may be more likely to use them for 
recreational reasons.  
Motivation findings across prescription drug classes. Two studies looked at 
motivations across prescription drug classes to assess NUMPD in general, not limited by 
prescription drug class. Both of these studies were discussed above and were cross-sectional 
research using college students as participants. One study was conducted in the United States and 
focused on sex differences in the motivations for NMUPD in general (McCabe et al., 2009). The 
other study was conducted in Lebanon and investigated if motivations across prescription drug 
class for NMUPD differed based on where young adults got their prescriptions (Ghandour et al., 
2012). 
McCabe and colleagues (2009) found sex differences across prescription drug classes in 
their sample of American college students. For instance, women reported more self-treatment 
motives as compared to men, while men reported more recreational and mixed (self-treatment 
and recreational) motives. Ghandour and colleagues (2012) found that type of motivation varied 
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not only based on prescription medication class, but also based on other variables. For example, 
Lebanese students who reported obtaining sleeping, anxiety, and pain medications from their 
parents in general were using them for their intended purpose. Similarly, students who obtained 
their stimulant medications from a doctor or pharmacist reported using the medication non-
medically for its intended purpose only, though it was not how the doctor prescribed the 
medication. However, students who obtained stimulants from friends and family members other 
than parents were more likely to report using the medication for other unintended purposes (e.g., 
to get high).  
As these were the only two studies to research the motivations for NMUPD across 
multiple prescription classes and they occurred in different cultures and investigated different 
variables it is difficult to draw overall conclusions from their findings. Still, though varied, these 
results suggest that motivations for NMUPD are influenced by different factors. Also, the 
findings are a reminder that context matters when researching motivations and needs to be 
considered when interpreting results from any study.  
Difficulties in reviewing NMUPD motivation results. There are many reasons why 
evaluating research on NMUPD as a whole is difficult. First, the definition of “non-medical” use 
varies between studies. Some definitions only include illegal act of using a medication without a 
prescription, or researchers remove participants from their data set who report having a 
prescription for medications (e.g., DeSantis et al., 2008; Dussault & Weyandt, 2013; Franke et 
al., 2011; Jeffers & Benotsch, 2014). Eliminating these participants is concerning because they 
may still be using their own prescription non-medically. Indeed, studies that have included and 
analyzed data of young adults who do have prescriptions for medications find that participants 
are using their medications non-medically. For example, in terms of stimulant medications 
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prevalence rates of young adults using their own prescription non-medically range from 2% to 
47% in studies discussed. Further, differences in motivations were noted in at least two of these 
studies. Results found that individuals who misuse others’ prescriptions reported more 
recreational motives than those who use their own medications non-medically (Gallucci et al., 
2014), or used prescriptions less “to control ADHD symptoms” (Hartung et al., 2013). These 
findings suggest that both groups of young adults need to be considered when investigating 
NMUPD and studies that have not included students who have a prescription for medications 
may be underreporting the prevalence of NMUPD. Further, only studies with prescription 
stimulants have specifically looked at the differences between these populations. It is not clear if 
similar findings exist for prescription opioid and CNS depressant non-medical users.  
Other studies have included participants who have a prescription but ask about tolerance 
(e.g., use for longer periods than prescribe; Ghandour et al., 2012) and motives in their “non-
medical” definition (e.g., for reasons other than indicated by a prescription; Lord et al., 2009). 
Additionally, one researcher only included the motive “to get high” to infer NMUPD 
(Upadhyaya et al., 2005). Other researchers do not state that they defined NMUPD, thereby 
leaving the definition of “non-medical” use to the discretion of the participants (e.g., Rozenbroek 
& Rothstein, 2011; Stone & Merlo, 2011; Tuttle et al., 2010; Weyandt et al., 2009). This lack of 
consistency across studies makes comparisons difficult and drawing conclusions complicated. 
Another inconsistency in the research is that different medications were grouped and 
termed differently across studies (e.g., sedative/anxiety vs. sleeping pills, etc.). In particular, 
CNS depressants had the most varied definition across studies. This is probably because CNS 
depressants cover a variety of medications. Only one study grouped CNS depressants together 
into a single category (Rozenbroek & Rothstein, 2011). However, using the broad category of 
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CNS depressants may not allow researchers to find differences in motivations between the 
categories within that class of medication. For instance, McCabe and colleagues (2009) found 
differences between different motivational subtypes. The self-treatment subtype was the most 
prevalent for the non-medical use of sleeping medications, where the recreational subtype was 
most prevalent for sedative/anxiety medications. University students in the United Kingdom also 
endorsed using sedatives more to get high as compared to sleeping aids, as they were defined in 
the study (Holloway & Bennett, 2012). Therefore, results that group different types of CNS 
depressants together may be missing some of the subtleties between the different types of 
medications. 
Motivations also were not consistently assessed across studies. Some studies included 
very broad motivations (e.g., “makes me feel good,” Rozenbroek & Rothstein, 2011).  This 
makes it difficult to pinpoint non-medical users real motivation as it is unclear to determine if 
they were using the drug as it was intended for example, or for other more recreational reasons. 
Most other studies had more specific motivations listed, and found differences in the more 
nuanced responses. Other studies combined motivations like “to help me study/perform better at 
school” (Rozenbroek & Rothstein, 2011). These motives are double-barreled, and there may be 
students who are non-medically using prescription drugs for self-treatment reasons (e.g., using 
opioids to treat chronic pain) and therefore, it may help them perform better at school which is 
different than using that medication to help them study. The lack of specificity may make 
findings difficult to interpret and may not be as helpful in developing prevention or intervention 
efforts.   
Two studies used a specific scale to assess the motivations to use prescription drugs non-
medically. Dussault and Weyandt (2013) used the Stimulant Survey Questionnaire (SSQ), 
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developed by Weyandt and colleagues (2009) for the study of the non-medical use of 
prescription stimulant medications. Within this scale, participants were able to rate their 
likeliness of different motivations for the non-medical use of stimulants on a scale of 1 (never) to 
5 (always). The reliability for this factor was the strongest of all the scales factors though (α = 
.92). However, within the scoring of this scale motivations are not specifically highlighted, but 
are grouped together in a factor with other questions about context (e.g., use at parties), 
administration (e.g., “I have snorted prescription stimulants”), beliefs about harm (e.g., “using 
prescription stimulants occasionally is harmless”), knowledge about prescription stimulants and 
being offered prescription stimulants. This can make interpretations from studies using these 
scaled more difficult as more than just motivations are considered, confounding potential 
outcomes. Further, this scale only assesses motivations for the use of prescription stimulants.  
Other authors reported piloting their questions first (DeSantis et al., 2008; McNiel et al., 
2011), while others stated that they based their questions on previous research (Clegg-Kraynok et 
al., 2011; Gallucci et al., 2014; Hall et al., 2005; Hartung et al., 2013; Jeffers & Benotsch, 2014; 
Judson & Langdon, 2009; Stone & Merlo, 2011). One study reported using both methods 
(Holloway & Bennett, 2012). However, almost all modified the motivations provided in previous 
work. Garnier-Dykstra and colleagues (2012) and Lookatch and colleagues (2012) on the other 
hand, recorded students answers and then coded them into motivational categories. Finally, some 
of the studies had young adults choose or list one motive (Barrett et al., 2005; Dupont et al., 
2008; Franke et al., 2011; Gallucci et al., 2014; Holloway & Bennett, 2012; McNiel et al., 2011; 
Rozenbroek & Rothstein, 2011; Stone & Merlo, 2011; Upadhyaya et al., 2010), while the rest 
allowed for the selection of multiple motivations (Advokat et al., 2008; Bavarian et al., 2013; 
Clegg-Kraynok et al., 2011; DeSantis et al., 2008; Dussault & Weyandt, 2013; Garnier-Dykstra 
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et al., 2012; Ghandour et al., 2012; Hall et al., 2005; Hartung et al., 2013; Herman et al., 2011; 
Judson & Langdon, 2009; Lookatch et al., 2012; Lord et al., 2009; McCabe et al., 2009; Peterkin 
et al., 2011; Prudhomme White et al., 2006; Rabiner, Anastopoulos, Costello, Hoyle, McCabe, & 
Swartzwelder, 2009a; Rabiner, Anastopoulos, Costello, Hoyle, McCabe, & Swartzwelder, 
2009b; Teter et al., 2005; Teter et al., 2006; Tuttle et al., 2010; Weyandt et al., 2009). The 
varying measurement models add to the complication of interpreting results across studies.  
Limitations of past research. The overwhelming majority of the work on motivations 
for NMUPD in young adults is limited in scope. Most of the research has been conducted cross-
sectionally on motivations for the non-medical use of stimulant medications in student samples 
from the United States. There is especially a lack of longitudinal research in this population, as 
well as studies on the motivations to use CNS depressants non-medically. Also, although a few 
more studies have investigated the motives for opioid non-medical use, there is still a dearth of 
knowledge in this area. Since, as expected due to their different therapeutic properties, the 
motivations behind the different classes of prescription medications vary, this research is 
imperative and may be able to further prevention and intervention efforts that focus not only on 
stimulants, but on prescription opioids and CNS depressants as well.  
Research on motivations also needs to include young adults who are not currently 
students in higher education. Only two studies reached out to young adults in other areas. Franke 
and colleagues (2011) included young adults in Germany who were in vocational training, 
preparing for university or obtaining a job. Upadhyaya and colleagues (2010) used the Harris 
Poll Online panel to connect to young adults outside of academia in the United States. 
Impressively, through different sampling techniques, about half of the sample in Upadhyaya and 
colleagues (2010) consisted of young adults that did not identify as college students. Given that 
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this sample reported using stimulants non-medically both as the medications were intended and 
for recreational purposes, similar to college students, there may be some similar treatment 
approaches to both groups. As both of these studies only investigated the motives for non-
medical stimulant use, there is a need for research on the motivations for non-college enrolled 
young adults’ non-medical use of other prescription medications. However, it is important to 
note non-medical use of at least stimulants tends to be more prevalent in full-time college 
students as compared to those who are not in college or are only part-time students (SAMHSA, 
2009). This suggests that young adults not in college may be at less risk for these behaviors and 
the associated negative outcomes. More research needs to be conducted with other prescription 
medication classes to determine if this pattern is replicated. 
Present Study 
NMUPD is a significant and growing public health concern with young adults at great 
risk for use, abuse, and related negative outcomes. The most substantial gap in the current 
literature is the lack of comprehensive longitudinal investigations assessing motivations for 
NMUPD for multiple prescription drug classes in a representative sample of young adults and 
how these motivations may change over time. The present study contributes to the literature on 
NMUPD by addressing some of the limitations in previous research investigating the motivations 
to use prescription drugs non-medically. First, the sample consisted of a nationally representative 
sample of young adults that have been followed longitudinally across three biennial follow-up 
waves (modal ages 19/20 to 23/24 years from wave 1 to 3). With this sample, information about 
how motivations change over time in a representative sample of young adults were assessed. 
Also, if there are differences over time for motivations for NMUPD of young adults based on 
sex, or who attend college, was researched. If motivations are different for young adults who 
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endorsed using in high school, or if motivations for NMUPD change over time for new users 
were investigated as well. Further, specific motivations for the non-medical use of prescription 
stimulants, opioids, and CNS depressants were studied, expanding the knowledge on less 
researched prescription drug classes. The strengths of the present study clearly advance the 
current NMUPD literature. 
This study has the potential to help prevention and intervention efforts in several ways. 
For example, by identifying if motivations change over time, developmentally appropriate efforts 
to reflect these changes can be enacted. Additionally, if the change in motivations is different for 
young adults in college as compared to their peers not in college, or based on sex, the best ways 
to intervene with these unique populations can be better understood to increase effectiveness. 
Finally, results from this study can help to explain if there are differences in motivations for 
young adults who started NMUPD in high school or if there are changes in motivations over time 
for new users. These findings in particular can help to inform prevention efforts by targeting 
what motivates young adults to initiate NMUPD. 
A series of generalized estimating equations (GEE) repeated measure analyses tested 
variations in motivations of NMUPD through secondary data analyses. Separate equations were 
developed for each of the following: (1) non-medical use of stimulants, (2) non-medical use of 
CNS depressants, and (3) non-medical use of prescription opioids. Following the bivariate 
analyses, each equation was reestimated to test if sex or attending college moderated the relation 
of motivations for NMUPD over time. Binary logistic regression models were then used to 
estimate if individuals who reported NMUPD in high school endorsed different motivations than 
individuals who reported initiating use in wave 1 (e.g., beginning of young adulthood). Finally, 
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GEE models tested whether NMUPD motivations changed over time for new users. Again, 
separate analyses were conducted for each class of prescription drugs.  
Based on the developmental theory of young adults and previously examined research the 
following results are hypothesized.  
Statement of the Hypotheses 
 Hypothesis 1. It is predicted that the motivations to feel good or get high, for 
experimentation, and boredom will decrease over time across all prescription drugs classes as 
young adults move towards more stability. 
Hypothesis 2. It is predicted that “self-treatment” motives (i.e., stimulants: to stay awake, 
to get more energy, to help me study, and to help me lose weight; opioids: to relax or relieve 
tension, to get sleep, and to relieve physical pain and; CNS depressants: to relax or relieve 
tension, and to get sleep) as well as addiction motives (i.e., because I am “hooked”—I feel I have 
to have them) will increase over time across all prescription drug classes as exposure to 
prescription drugs and the risk for psychiatric problems increases.  
Hypothesis 3. It is predicted that there will be no change over time in the following 
motives: to seek deeper insights and understanding, because of anger or frustration, to get 
through the day, to increase the effects of some other drug(s), to decrease (offset) the effects of 
some other drug(s), as a substitute for heroin, and to control coughing. 
Hypothesis 4. It is predicted that sex differences will be observed for CNS depressant 
and opioid prescription drug classes, such that males will endorse more recreational motivations 
(i.e., to experiment, to feel good or get high, to seek deeper insights and understanding, to have a 
good time with my friends, to fit in with a group I like, because of boredom, to increase or 
decrease the effects of some other drug(s)e (offset) the effects of some other drug(s)), as 
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compared to females who will report more self-treatment motivations, or using the medications 
as they are clinically intended. Moderation analyses are largely exploratory given the lack of 
previous research in this area. 
Hypothesis 5. It is predicted that college attendance will not moderate the relations of 
change of motives over time across all prescription drug classes, such that both young adults in 
and out of college will experience the same changes in motives over time because they are all 
experiencing the same developmental life stage and associated changes.  
Hypothesis 6. It is predicted that young adults who started NMUPD in high school, 
compared to their peers who initiated NMUPD right after high school will be more likely to 
endorse recreational motivations.  
Hypothesis 7. It is predicted that over time the motivations for new non-medical users of 
prescription drugs will be similar to those of continued users, such that all young adults 
experience the same changes in motivations over time because they are all experiencing the same 
developmental life stage and associated changes. 
Method 
Participants 
The sample consisted of 14,990 participants who were surveyed in their first, second, and 
third biennial follow-up surveys following high school completion (waves 1, 2, and 3, 
respectively) from 1976 to 2013 as part of the Monitoring the Future (MTF) project. Due to the 
aims of the proposed study and concerns about sample size, the 36 cohorts were combined and 
the analyses were conducted on all available data. After accounting for sampling bias, the sample 
consisted of 48% male and 73% White participants (weighted). Based on previous studies 
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analyzing similar data from this project, the retention rate was estimated to be just below 50% 
(McCabe et al., 2014).  
Measures 
Using six randomly distributed questionnaire forms, the MTF assesses demographic and 
psychosocial characteristics and standard measures of substance use. 
Demographics. Demographics were assessed at wave 1 and consisted of participant self-
reports of age, sex (i.e., male/female), race/ethnicity (i.e., White/non-White), and if they were 
enrolled in an academic course (i.e., During March of this year, were you taking courses at any 
school or college?). 
NMUPD. NMUPD was assessed at all three waves with items asking respondents on 
how many occasions (if any) they had used prescription medications on their own, without a 
doctor’s orders during the past 12 months. There were separate questions for each prescription 
medication class: (1) prescription stimulants (e.g., Dexedrine, Ritalin, Adderall, Concerta, 
Methamphetamine); (2) prescription CNS depressants/tranquilizers (e.g., Librium, Valium, 
Xanax, Soma, Serax, Ativan, Klonopin); and (3) prescription opioids (e.g., Methadone, Codeine, 
OxyContin, Percodan, Opium, Demerol, Percocet, Ultram, Morphine, and Vicodin). The 
response scale was (1) no occasions, (2) one to two occasions, (3) three to five occasions, (4) six 
to nine occasions, (5) 10–19 occasions, (6) 20–39 occasions and (7) 40 or more occasions. 
Motivations for NMUPD. Motivations for NMUPD were assessed by asking 
participants who reported past-year NMUPD to indicate the most important reasons for NMUPD 
from a check-all-that-apply list of binary items. As noted in Table 1, all prescription drug classes 
listed the following motives: (a) to experiment—to see what it’s like, (b) to relax or relieve 
tension, (c) to feel good or get high, (d) to seek deeper insights and understanding, (e) to have a 
     
41 
 
good time with my friends, (f) to fit in with a group I like, (g) to get away from my problems or 
troubles, (h) because of boredom, nothing else to do, (i) because of anger or frustration, (j) to get 
through the day, (k) to increase the effects of some other drug(s), (l) to decrease (offset) the 
effects of some other drug(s), and (m) because I am “hooked”—I feel I have to have them.  
Table 1. 
NMUPD motivations assessed by prescription drug class 
Stimulants CNS depressants Opioids 
1. To experiment—to see 
what it’s like 
1. To experiment—to see 
what it’s like 
1. To experiment—to see 
what it’s like 
2. To relax or relieve tension 2. To relax or relieve tension 2. To relax or relieve tension 
3. To feel good or get high 3. To feel good or get high 3. To feel good or get high 
4. To seek deeper insights and 
understanding 
4. To seek deeper insights and 
understanding 
4. To seek deeper insights and 
understanding 
5. To have a good time with 
my friends 
5. To have a good time with 
my friends 
5. To have a good time with 
my friends 
6. To fit in with a group I like 6. To fit in with a group I like 6. To fit in with a group I like 
7. To get away from my 
problems or troubles 
7. To get away from my 
problems or troubles 
7. To get away from my 
problems or troubles 
8. Because of boredom, 
nothing else to 
do
  
8. Because of boredom, 
nothing else to do 
8. Because of boredom, 
nothing else to do 
9. Because of anger or 
frustration 
9. Because of anger or 
frustration 
9. Because of anger or 
frustration 
10. To get through the day 10. To get through the day 10. To get through the day 
11. To increase the effects of 
some other drug(s) 
11. To increase the effects of 
some other drug(s) 
11. To increase the effects of 
some other drug(s) 
12. To decrease (offset) the 
effects of some other 
drug(s) 
12. To decrease (offset) the 
effects of some other 
drug(s) 
12. To decrease (offset) the 
effects of some other 
drug(s) 
13. To stay awake  13. To get sleep  13. To get sleep  
14. To get more energy  14. Because I am “hooked”—I 
feel I have to have them 
14. As a substitute for heroin 
15. To help me lose weight  15. Because I am “hooked”—I 
feel I have to have them  
16. To relieve physical pain 
16. Because I am “hooked”—I 
feel I have to have them  
17. To help me study 
15. To relieve physical pain 
 17. To control coughing 
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Specific motives for stimulants included: (a) to stay awake, (b) to get more energy, (c) to 
help me study, and (d) to help me lose weight. Both CNS depressants and opioids included the 
motives, “to get sleep,” and “to relieve physical pain.” Opioids had the additional motives, “as a 
substitute for heroin,” and “to control coughing.” 
Procedures 
According to the MTF website (The Regents of the University of Michigan, 2014), the 
MTF project begun in 1975 with the goal to study changes in the beliefs, attitudes, and behavior 
of young people in the United States. The MTF project is a repeated series of surveys in which 
the same segments of the population (8th, 10th, and 12th graders; college students; and young 
adults) are presented with the same set of questions over a period of years to see how answers 
change over time. The project has been conducted under a series of research grants from NIDA, 
a part of the National Institutes of Health. Surveys have been carried out each year since 1975 by 
the University of Michigan Survey Research Center. The MTF uses a three-stage sampling 
procedure to gather a nationally representative sample of students. In stage 1, geographic areas or 
primary sampling units are selected; in stage 2, schools within primary sampling units are 
selected (with probability proportionate to class size); and in stage 3, students within schools are 
selected. Within each school, up to 350 students may be included. In schools with fewer 
students, the usual procedure is to include all of them in the data collection. In larger schools, a 
subset of students is selected either by randomly sampling entire classrooms or by some other 
random method that is judged to be unbiased.  
For the in-school survey, about 10 days before the administration, the students are given 
flyers explaining the study. Also, advance letters to parents inform them about the study and 
provide them a means for declining their child's participation if they so desire. The actual 
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questionnaire administrations are conducted by the local Institute for Social Research 
representatives and their assistants, following standardized procedures detailed in a project 
instruction manual. The questionnaires are group administered in classrooms during a normal 
class period whenever possible; however, circumstances in some schools require the use of larger 
group administrations. For those students selected to participate in the follow-up surveys, the 
questionnaires are mailed to the participants with a return, self-addressed, stamped envelope and 
a small monetary gift from the University of Michigan as a token of appreciation. Because so 
many questions are included in the MTF, much of the questionnaire content is divided into six 
different questionnaire forms, which are randomly distributed. This approach results in six 
virtually identical subsamples. The questionnaires sent in the follow-up survey are directly 
comparable to the base year questionnaires, both in content and in numbers of questionnaire 
forms. The measures relevant for this study were asked on Form 1; therefore, this study focused 
on the subsamples receiving Form 1 within each cohort. 
Each year about 16,000 students in approximately 133 public and private high schools 
nationwide participate by completing surveys administered in classrooms. A randomly selected 
sample of approximately 2,400 students from each senior class is followed up biannually after 
high school on a continuing basis. These respondents receive the mail questionnaire at their 
home, which they complete and return to MTF. The biennial follow-up surveys begin 1 year 
after high school for one random half of each cohort and 2 years after high school for the other 
half (for more information on the procedures see Bachman, Johnston, & O'Malley, 2014). For 
the purpose of the current study, the two halves were combined (combining modal ages 19/20, 
21/22 and 23/24 years) due to sample size concerns and reported lack of significant differences 
across the two halves on substance use measures (McCabe et al., 2014). The student response 
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rates for high school seniors ranged from 77% to 85% between 1976 and 2012 (Bachman et al., 
2014). The follow-up panel data for surveys through wave 3 is estimated to be approximately 
just below 50% (Bachman et al., 2014; McCabe et al., 2014). 
Data Analysis 
First, sampling weights were used to correct for any unequal probabilities of selection 
that occurred at any stage of sampling for all analyses so the results could be generalized to the 
national population. Then, descriptive statistics were calculated to examine the frequencies and 
distribution properties of each variable, as well to gain a better understanding of the sample 
demographics. This was followed by a test to determine if the missing data was missing 
completely at random (MCAR). 
A series of generalized estimating equations (GEE) repeated measure analyses tested 
variations in motivations of NMUPD using SPSS Version 23. GEE models were used because of 
their flexible approach to handling correlated data structures that arise from repeated measures of 
the same individuals over time (Diggle, Heagerty, Liang, & Zeger, 2013; Liang & Zeger, 1993; 
Zeger, Liang, & Albert, 1988; Zeger & Liang, 1992). Further, GEE can handle binary outcome 
data and time-varying and time-invariant predictors (Homish, Edwards, Eiden, & Leonard, 
2010). Additionally, GEE provides population averaged estimates, which is appropriate for 
nationally representative data. Although the correlation structure in GEE does not affect 
the marginal parameter estimates, it does affect the standard error estimates. Therefore, the GEE 
were conducted using an unstructured correlation matrix, which is a completely general 
correlation matrix. This decision was based on theory, comparison to the actual correlation 
matrixes, and Quasi-likelihood under Independence Model Criterion (QIC) comparisons. It 
should be noted that across models there were very small differences observed in the QIC values.  
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To answer the question if motivations of NMUPD change over the developmental period 
of young adulthood, GEE repeated measures equations were developed for non-medical users, in 
which each motive was, in turn, entered into a separate equation as the dependent variable, with 
wave (i.e., time) as the repeated factor in each equation. Separate equations were developed for 
each of the following: (1) non-medical use of stimulants, (2) non-medical use of CNS 
depressants, and (3) non-medical use of opioids. Next, analyses were conducted to determine if 
differences existed in the motivations for NMUPD based on young adults’ sex and college 
attendance. Following the bivariate analyses, each equation was re-estimated with wave as the 
repeated factor and the main effect of sex or college attendance and the first-order interaction of 
Sex/College Attendance*Wave included in the model. For all GEE analyses, a Wald chi-square 
test determined whether or not wave, sex, college attendance, and the Sex/College 
Attendance*Wave interaction were significantly associated with each dependent variable (i.e., 
each motivation). For models with significant chi-square tests, pairwise comparisons of 
estimated marginal means produced from these models were evaluated in order to determine 
among which waves the participants differed with respect to the dependent variable. The 
pairwise comparisons used a Bonferronni correction to control for the likelihood of making a 
Type I error as a result of multiple comparisons.  
Binary logistic regression models were then used to estimate if individuals who reported 
NMUPD in high school endorsed different motives than individuals who did not report NMUPD 
in high school on Wave 1 NMUPD. Each prescription drug class was investigated separately. For 
example, individuals who reported non-medical use of prescription stimulants in high school 
were compared to new non-medical users of prescription stimulants at Wave 1. Similarly, 
participants who reported non-medical use of prescription CNS depressants in high school were 
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compared to new non-medical users of CNS depressants at Wave 1. The same method was used 
for prescription opioids. Therefore, the groups may not be mutually exclusive as a participant 
may have endorsed non-medical use of more than one class of prescription medications either in 
high school or Wave 1.  
Finally, GEE repeated measures equations tested whether NMUPD motivations changed 
over time for new users. Again, separate analyses were conducted for each class of prescription 
drugs. Similarly as described above, GEE were developed for new non-medical users, in which 
each motive was, in turn, entered into a separate equation as the dependent variable, with wave 
as the repeating factor in each equation. Moderators were not included in these analyses because 
of sample size concerns. Additional post hoc analyses, including exploratory latent class 
analyses, are discussed in the results section. 
Results 
Descriptive Statistics 
Table 2 reports the sample demographics including sex, race/ethnicity, age, enrollment in 
college classes, and past year NMUPD for the total sample and for users, as appropriate. Of note, 
most individuals reported infrequent use (1-2 times in the past year) and the percentages of users 
attending college classes decreased over time for all prescription drug classes. Table 3 reports the 
frequencies and percentage of users that endorsed each motivation across all waves. It should be 
noted that some motives have smaller sample sizes as they were added to the study in later years. 
For stimulants, the top NMUPD motivations consistently included (in terms of high frequencies): 
to help me study, to stay awake, to get more energy, to feel good or get high, to experiment, and 
to help me lose weight. For CNS depressants, the top NMUPD motivations consistently 
included: to relax or relive tension, to get sleep, to feel good or get high, to experiment, and to 
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relieve physical pain. The frequencies of NMUPD motivations for prescription opioids were 
slightly more varied, but consistently included: to feel good to get high, to experiment, to relax 
or relieve tension, and to relieve physical pain. Table 4 reports the frequencies, means, and 
standard deviations of the number of motivations endorsed by users by prescription drug class to 
gain a better understanding of how many motives were endorsed overall. Across all prescription 
drug classes it was common to endorse more than one motive, but not more than four or five 
motives across all waves. 
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Table 2.  
Sample demographics for total sample and past year NMUPD users by prescription drug class 
Demographic Total sample Stimulants CNS depressants Opioids 
N 12,223   Wave 1 Wave 2 Wave 3 Wave 1 Wave 2 Wave 3 Wave 1 Wave 2 Wave 3 
Sex (n, % male) 5,789 (47.5)  288 
(43.6) 
273 
(44.7) 
185 
(47.5) 
123 
(36.1) 
126 
(40.9) 
119 
(40.8) 
153 
(41.9) 
148 
(43.1) 
113 
(42.1) 
Race/ethnicity  
(n, % White) 
8,736 (72.5)  582 
(88.6) 
529 
(87.6) 
335 
(85.8) 
295 
(88.3) 
273 
(89.1) 
254 
(86.6) 
322 
(88.6) 
301 
(89.6) 
231 
(86.1) 
 Wave 1 Wave 2 Wave 3          
N of usersa 9,237 8,629 7,836 757 724 466 428 444 406 549 492 376 
Age (M(SD))a 19.52 
(0.46) 
21.49 
(0.44) 
23.47 
(0.43) 
19.43 
(0.26) 
21.47 
(0.26) 
23.38 
(0.26) 
19.51 
(0.24) 
21.42 
(0.23) 
23.52 
(0.24) 
19.49 
(0.24) 
21.49 
(0.29) 
23.47 
(0.28) 
             
Taking college 
classes (n, %) 
5,753 
(68.1) 
4,447 
(56.8) 
2,193 
(30.7) 
398 
(60.7) 
295 
(48.6) 
113 
(29.0) 
203 
(60.1) 
148 
(48.4) 
84 
(28.8) 
251 
(68.1) 
192 
(56.5) 
88 
(32.9) 
             
Number of occasions used in 
past year (n (%)) 
           
0    7,719 
(92.1) 
7,152 
(92.1) 
6,721 
(94.5) 
8,023 
(95.9) 
7,450 
(96.0) 
6,820 
(95.9) 
7,949 
(95.6) 
7,396 
(95.6) 
6,822 
(96.2) 
1-2    217 
(2.6) 
214 
(2.8) 
133 
(1.9) 
183 
(2.2) 
160 
(2.1) 
147 
(2.1) 
189 
(2.3) 
174 
(2.2) 
132 
(1.9) 
3-5    131 
(1.6) 
133 
(1.7) 
78 (1.1) 78 (0.9) 57 (0.7) 57 (0.8) 79 (0.9) 77 (1.0) 63 (0.9) 
6-9    98 (1.2) 77 (1.0) 50 (0.7) 36 (0.4) 46 (0.6) 39 (0.6) 46 (0.6) 35 (0.4) 29 (0.4) 
10-19    95 (1.1) 78 (1.0) 51 (0.7) 27 (0.3) 28 (0.4) 24 (0.3) 27 (0.3) 24 (0.3) 18 (0.2) 
20-39    52 (0.6) 51 (0.7) 38 (0.5) 9 (0.1) 9 (0.1) 9 (0.1) 14 (0.2) 14 (0.2) 14 (0.2) 
40+    73 (0.9) 61 (0.8) 44 (0.6) 10 (0.1) 11 (0.1) 18 (0.2) 14 (0.2) 19 (0.2) 14 (0.2) 
Note. All descriptive statistics are weighted. All percentages are reported as valid percentages, not including participants who had missing 
values. 
a Information provided by researchers at University of Michigan with access to full data set.  
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Table 3.  
Frequencies of endorsed NMUPD motivations over time and percentage of users 
NMUPD Motivation Wave 1  
n (% of users) 
Wave 2   
n (% of users) 
Wave 3  
n (% of users) 
Stimulants (n) 645 587 376 
To experiment—to see what it’s like 272 (42.2) 206 (35.1) 99 (26.4) 
To relax or relieve tension 73 (11.3) 46 (7.9) 24 (6.3) 
To feel good or get high 254 (39.3) 218 (37.2) 131 (34.8) 
To seek deeper insights and understanding 29 (4.4) 21 (3.5) 17 (4.5) 
To have a good time with my friends 175 (27.1) 161 (27.4) 100 (26.5) 
To fit in with a group I like 11 (1.7) 12 (2.0)  9 (2.5) 
To get away from my problems or troubles 45 (7.0) 32 (5.5) 17 (4.5) 
Because of boredom, nothing else to do  66 (10.2) 49 (8.4) 31 (8.3) 
Because of anger or frustration 42 (6.6) 20 (3.3)  13 (3.5) 
To get through the day 159 (24.7) 50 (25.6)  91 (24.1) 
To increase the effects of some other drug(s) 61 (9.4) 41 (7.0) 33 (8.8) 
To decrease (offset) the effects of some other drug(s) 27 (4.1) 27 (4.7)  20 (5.4) 
To stay awake  416 (64.5) 381 (64.8)  243 (64.6) 
To get more energy  390 (60.5) 371 (63.1) 264 (70.2) 
To help me lose weight  205 (31.8) 182 (31.0) 130 (34.5) 
Because I am “hooked”—I feel I have to have them  9 (1.3) 8 (1.3) 4 (1.1) 
To help me studya 35 (75.9) 56 (74.9) 35 (63.6) 
    
CNS depressants (n) 313 285 271 
To experiment—to see what it’s like 114 (36.4) 93 (32.6) 76 (28.2) 
To relax or relieve tension 230 (73.3) 216 (75.8) 217 (80.1) 
To feel good or get high 120 (38.2) 17 (40.9) 98 (36.2) 
To seek deeper insights and understanding 10 (3.1) 8 (2.9) 4 (1.5) 
To have a good time with my friends 60 (19.1) 69 (24.3) 46 (17.1) 
To fit in with a group I like 2 (0.6) 5 (1.8) 4 (1.5) 
To get away from my problems or troubles 59 (18.8) 40 (14.1) 55 (20.4) 
Because of boredom, nothing else to do 33 (10.5) 31 (11.0) 25 (9.2) 
Because of anger or frustration 42 (13.3) 40 (13.9) 47 (17.5) 
To get through the day 20 (6.4) 14 (4.9) 25 (9.1) 
To increase the effects of some other drug(s) 44  (14.0) 43 (15.1) 32 (11.8) 
To decrease (offset) the effects of some other drug(s) 10 (3.1) 15 (5.3) 24 (8.9) 
To get sleep  146 (46.6) 131 (45.9) 144 (53.3) 
Because I am “hooked”—I feel I have to have them 30 (9.5) 21 (7.2) 6 (2.3) 
To relieve physical painb 81 (26.2) 95 (32.9) 93 (34.3) 
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NMUPD Motivation Wave 1  
n (% of users) 
Wave 2   
n (% of users) 
Wave 3  
n (% of users) 
Opioids (n) 325 304 242 
To experiment—to see what it’s like 168 (51.7) 120 (39.5) 79 (32.6) 
To relax or relieve tension 157 (48.3) 166 (54.4) 130 (53.8) 
To feel good or get high 179 (55.1) 145 (47.8) 118 (48.8) 
To seek deeper insights and understanding 16 (5.0) 12 (3.8) 11 (4.7) 
To have a good time with my friends 96 (29.5) 82 (26.8) 57 (23.4) 
To fit in with a group I like 5 (1.4) 10 (3.2) 3 (1.1) 
To get away from my problems or troubles 51 (15.8) 43 (14.1) 36 (15.0) 
Because of boredom, nothing else to do 53 (16.2) 36 (11.9) 32 (13.1) 
Because of anger or frustration 30 (9.2) 31 (10.2) 20 (8.1) 
To get through the day 22 (6.8) 19 (6.1) 22 (8.9) 
To increase the effects of some other drug(s) 55 (17.0) 47 (15.3) 34 (14.0) 
To decrease (offset) the effects of some other drug(s) 9 (2.9) 8 (2.5) 11 (4.5) 
To get sleep  91 (28.1) 87 (28.7) 70 (29.0) 
As a substitute for heroin 6 (1.8) 7 (2.3) 6 (2.3) 
Because I am “hooked”—I feel I have to have them  25 (7.8) 19 (6.4) 10 (4.3) 
To relieve physical painc 151 (46.8) 178 (58.0) 157 (64.6) 
To control coughingc 31 (9.5) 32 (10.5) 25 (10.2) 
Note. NMUPD = Non-medical use of prescription drugs. All frequencies and percentages are weighted.  
a Motivation added in 2009, sample size: Wave 1 = 46, Wave 2 = 74, Wave 3 = 55 
b Motivation added in 1981, sample size: Wave 1 = 309, Wave 2 = 288, Wave 3 = 271 
c Motivation added in 1981, sample size: Wave 1 = 324, Wave 2 = 307, Wave 3 = 242 
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Table 4. 
Frequencies, means, and standard deviations of number of motives endorsed by users by 
prescription drug class 
 
Number of Motives Endorsed Wave 1  Wave 2  Wave 3  
Stimulants (M (SD)) 3.73 (2.31) 3.47 (2.11) 3.49 (2.21) 
1 (n (% of users)) 195 (16.4) 167 (17.1) 91 (14.9) 
2 (n (% of users)) 216 (18.1) 202 (20.7) 151 (24.7) 
3 (n (% of users)) 228 (19.1) 194 (19.9) 124 (20.3) 
4 (n (% of users)) 183 (15.4) 156 (16.0) 91 (14.9) 
5 (n (% of users)) 142 (11.9) 114 (11.7) 64 (10.5) 
6 (n (% of users)) 89 (7.5) 62 (6.4) 36 (5.9) 
7 (n (% of users)) 60 (5.0) 32 (3.3) 20 (3.3.) 
8 (n (% of users)) 29 (2.4) 18 (1.8) 12 (2.0) 
9 (n (% of users)) 21 (1.8) 9 (0.9) 8 (1.3) 
10 (n (% of users)) 10 (0.8) 9 (0.9) 9 (1.5) 
11 (n (% of users)) 9 (0.8) 7 (0.7) 1 (0.2) 
12 (n (% of users)) 4 (0.3) 3 (0.3) 1 (0.2) 
13 (n (% of users)) 1 (0.1) 1 (0.1) 1 (0.2) 
14 (n (% of users)) 3 (0.3) 0 (0.0) 2 (0.3) 
15 (n (% of users)) 1 (0.1) 0 (0.0) 0 (0.0) 
16 (n (% of users)) 0 (0.0) 0 (0.0) 0 (0.0) 
17 (n (% of users)) 0 (0.0) 0 (0.0) 0 (0.0) 
    
CNS Depressants (M (SD)) 3.47 (2.20) 3.45 (2.26) 3.49 (2.31) 
1 (n (% of users)) 109 (18.9) 98 (18.8) 77 (17.5) 
2 (n (% of users)) 115 (19.9) 125 (24.0) 102 (23.1) 
3 (n (% of users)) 119 (20.6) 92 (17.7) 90 (20.4) 
4 (n (% of users)) 86 (14.9) 60 (11.5) 62 (14.1) 
5 (n (% of users)) 55 (9.5) 62 (11.9) 39 (8.8) 
6 (n (% of users)) 41 (7.1) 26 (5.0) 28 (6.3) 
7 (n (% of users)) 19 (3.3) 23 (4.4) 14 (3.2) 
8 (n (% of users)) 19 (3.3) 13 (2.5) 10 (2.3) 
9 (n (% of users)) 3 (0.5) 17 (3.3) 6 (1.4) 
10 (n (% of users)) 6 (1.0) 2 (0.4) 7 (1.6) 
11 (n (% of users)) 3 (0.5) 0 (0.0) 1 (0.2) 
12 (n (% of users)) 0 (0.0) 0 (0.0) 3 (0.7) 
13 (n (% of users)) 2 (0.3) 0 (0.0) 0 (0.0) 
14 (n (% of users)) 1 (0.2) 0 (0.0) 2 (0.5) 
15 (n (% of users)) 0 (0.0) 2 (0.4) 0 (0.0) 
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Number of Motives Endorsed Wave 1  Wave 2  Wave 3  
Opioids (M (SD)) 3.75 (2.46) 3.58 (3.73) 3.53 (2.54) 
1 (n (% of users)) 106 (17.4) 100 (19.7) 80 (21.0) 
2 (n (% of users)) 115 (18.9) 95 (18.7) 84 (22.0) 
3 (n (% of users)) 122 (20.0) 83 (16.4) 69 (18.1) 
4 (n (% of users)) 80 (13.1) 79 (15.6) 44 (11.5) 
5 (n (% of users)) 66 (10.8) 50 (9.9) 35 (9.2) 
6 (n (% of users)) 36 (5.9) 33 (6.5) 25 (6.6) 
7 (n (% of users)) 31 (5.1) 29 (5.7) 15 (3.9) 
8 (n (% of users)) 22 (3.6) 14 (2.8) 11 (2.9) 
9 (n (% of users)) 12 (2.0) 2 (0.4) 7 (1.8) 
10 (n (% of users)) 6 (1.0) 9 (1.8) 3 (0.8) 
11 (n (% of users)) 6 (1.0) 5 (1.0) 2 (0.5) 
12 (n (% of users)) 4 (0.7) 4 (0.8) 1 (0.3) 
13 (n (% of users)) 1 (0.2) 2 (0.4) 2 (0.5) 
14 (n (% of users)) 2 (0.3) 0 (0.0) 1 (0.3) 
15 (n (% of users)) 0 (0.0) 0 (0.0) 1 (0.3) 
16 (n (% of users)) 0 (0.0) 0 (0.0) 1 (0.3) 
17 (n (% of users))  0 (0.0) 2 (0.4) 0 (0.0) 
Note. All frequencies and percentages are weighted. 
Missing Data Analyses 
  Since many of the analyses that were run operate under the assumption that the data is 
missing completely at random, missing data analyses were conducted. According to Little’s chi-
square statistic (Little, 1988) data was missing completely at random (MCAR), χ2 = 12882.59, df 
= 16252, p = 1.00. Regardless, as discussed previously, for tests that may be biased based on 
missing data patterns, other precautions were implemented. For example, the correlation 
structure was specified in the GEE analyses, even though GEE models are more flexible for 
missing data compared to other models (Zeger et al., 1988). 
Changes in NMUPD Motivations Across Young Adulthood 
 Table 5 reports the motivations that had significant differences across waves for all 
NMPUD users, including the Wald Chi-square statistic and results from the subsequent pairwise 
comparisons using Bonferroni corrections. Overall, there were relatively few motives that 
evidenced a main effect of time. For stimulants, in general, participants reported less 
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experimentation and more motivation to increase energy over time. For CNS depressants, 
participants reported more motivation to decrease the effects of other drugs and to relieve 
physical pain over time. For opioids, participants reported less experimentation, less boredom, 
and more motivation to relieve physical pain as they matured. Additionally, GEE models for the 
motivations of addiction for stimulants, and to decrease the effect of other drugs for opioids were 
unable to converge, potentially as a result of the small number of participants endorsing these 
motives across waves (i.e., 20 and 28; respectively).  
Table 5. 
Significant changes in NMUPD motivations across young adulthood for all users 
NMUPD Motivation Wald chi-square 
 
Pairwise comparisons 
Stimulants   
To experiment—to see what it’s like χ2 (2, N = 792) = 17.08*** Wave 1 > Wave 3*** 
Wave 2 > Wave 3** 
To get more energy  χ2 (2, N = 792) = 11.92** Wave 1 < Wave 3** 
   
CNS depressants   
To decrease (offset) the effects of some 
other drug(s) 
χ2 (2, N = 535) = 8.82* Wave 1 < Wave 3** 
To relieve physical pain χ2 (2, N = 534) = 6.23* Wave 1 < Wave 2* 
   
Opioids   
To experiment—to see what it’s like χ2 (2, N = 559) = 10.86** Wave 1 > Wave 2* 
Wave 1 > Wave 3* 
Because of boredom, nothing else to do χ2 (2, N = 559) = 10.86** Wave 1 > Wave 2* 
To relieve physical pain χ2 (2, N = 560) = 9.12* Wave 1 < Wave 3* 
Note. NMUPD = Non-medical use of prescription drugs. Unweighted sample sizes are reported for 
the Wald chi-square statistics. * p < .05, ** p < .01, *** p < .001. 
 
Sex as a Moderator in Changes in NMUPD Motivations 
 Table 6 reports the Wald chi-square statistics for NMUPD motivations that had a main 
effect for sex and/or significant moderation (Wave*Sex), along with the frequencies and 
percentages of the sex differences observed. For stimulants, significantly more males endorsed 
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the following motivations: experimentation, have a good time with friends, increase the effects 
of other drugs, decrease the effects of other drugs, and to stay awake. More females endorsed 
using stimulants non-medically to lose weight.  
For CNS depressants, more males endorsed the following motivations: experimentation, 
to feel good/get high, and have a good time with friends. More females endorsed being 
motivated to use CNS depressants non-medically to get sleep.  
For opioids, more males endorsed the following motivations: experimentation, to feel 
good/get high, and to have a good time with friends. More females endorsed using opioids non-
medically to get sleep, relieve physical pain, and to control coughing. 
Two motivations were moderated by sex, as indicated by a significant Wave*Sex 
interaction. These included to feel good/get high for stimulant medications and to have a good 
time with friends for CNS depressants.  
Additionally, GEE models for the following motivations were unable to converge or 
received an error for concerns about validity: addiction for stimulants, seeking deeper 
understanding, fit in with a group, boredom, to decrease the effects of other drugs for CNS 
depressants, and fit in with a group, to decrease the effect of other drugs, and as a substitute for 
heroin for opioids. Further, for the motivation to get through the day for stimulant medications, 
although a significant Wald chi-square was reported for a Wave*Sex moderation (χ2 (2, N = 790) 
= 11.40, p = .003), no significant findings were reported in the subsequent pairwise comparisons.   
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Table 6.  
Frequencies and percentages of users by sex and wave for significant GEE models, Wald chi-square and pairwise comparisons for 
main effect of sex and wave*sex 
 
NMUPD Motivation Wave 1  
Male: n (%) 
Female: n (%) 
Wave 2  
Male: n (%) 
Female: n (%) 
Wave 3 
Male: n (%) 
Female: n (%) 
Wald chi-square for sex Wald chi-square for Wave*Sex 
 
Stimulants      
To experiment—to see 
what it’s like 
127 (45.5) 
143 (39.4) 
109 (41.1) 
96 (30.3) 
57 (32.4) 
42 (21.1) 
χ2 (1, N = 790) = 8.94** 
Male > Female 
ns 
To feel good or get 
high 
110 (39.2) 
142 (39.4) 
103 (38.7) 
114 (36.0) 
73 (41.9) 
57 (28.7) 
ns χ2 (2, N = 790) = 10.27** 
Wave 1 females > Wave 3 females* 
Wave 3 males > Wave 3 females* 
To have a good time 
with my friends 
88 (31.3) 
86 (23.7) 
79 (29.5) 
82 (25.7) 
59 (33.7) 
41 (20.6) 
χ2 (1, N = 790) = 6.24* 
Male > Female 
ns 
To increase the effects 
of some other drug(s) 
36 (12.8)  
25 (6.8) 
26 (9.8) 
15 (4.7) 
21 (12.0) 
12 (5.9) 
χ2 (1, N = 790) = 12.02** 
Male > Female 
ns 
To decrease (offset) 
the effects of some other 
drug(s) 
17 (6.1) 
9 (2.6) 
17 (6.3) 
11 (3.4) 
14 (8.2) 
6 (3.0) 
χ2 (1, N = 790) = 8.75** 
Male > Female 
ns 
To stay awake  193 (68.9) 
221 (61.1) 
190 (71.5) 
188 (59.1) 
131 (75.0) 
108 (54.9) 
χ2 (1, N = 790) = 25.45*** 
Male > Female 
ns 
To help me lose 
weight  
24 (8.6) 
180 (49.8) 
32 (11.9) 
149 (47.0) 
19 (10.7) 
110 (55.9) 
χ2 (1, N = 790) = 120.58*** 
Female > Male 
ns 
      
CNS depressants      
To experiment—to see 
what it’s like 
50 (44.6) 
63 (31.6) 
57 (47.9) 
36 (21.7) 
44 (40.2) 
32 (20.0) 
χ2 (1, N = 535) = 27.85*** 
Male > Female 
ns 
To feel good or get 
high 
52 (47.0) 
66 (33.1) 
66 (55.5) 
50 (30.4) 
55 (49.8) 
43 (26.6) 
χ2 (1, N = 535) = 15.56*** 
Male > Female 
ns 
To have a good time 
with my friends 
29 (26.3) 
30 (15.1) 
43 (36.3) 
26 (15.7) 
28 (25.1) 
19 (11.6) 
χ2 (1, N = 535) = 6.31* 
Male > Female 
χ2 (1, N = 535) = 6.69* 
Wave 1 females < Wave 2 males*  
Wave 2 females < Wave 2 males* 
To get sleep  45 (40.7) 
100 (49.9) 
44 (36.9) 
87 (52.3) 
54 (48.9) 
90 (56.3) 
χ2 (1, N = 535) = 5.77** 
Female > Male 
ns 
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NMUPD Motivation Wave 1  
Male: n (%) 
Female: n (%) 
Wave 2  
Male: n (%) 
Female: n (%) 
Wave 3 
Male: n (%) 
Female: n (%) 
Wald chi-square for sex Wald chi-square for Wave*Sex 
 
Opioids      
To experiment—to see 
what it’s like 
91 (65.0) 
75 (41.1) 
69 (51.1) 
51 (30.1) 
45 (44.2) 
33 (24.1) 
χ2 (1, N = 557) = 24.75*** 
Male > Female 
ns 
To feel good or get 
high 
89 (63.8) 
89 (48.7) 
81 (59.7) 
64 (38.0) 
64 (62.3) 
54 (39.3) 
χ2 (1, N = 557) = 12.40*** 
Male > Female 
ns 
To have a good time 
with my friends 
55 (39.0) 
41 (22.4) 
46 (34.2) 
35 (21.0) 
34 (32.8) 
23 (16.6) 
χ2 (1, N = 557) = 11.81*** 
Male > Female 
ns 
To get sleep  28 (19.8) 
64 (34.9) 
31 (22.6) 
57 (33.7) 
25 (24.7) 
44 (31.8) 
χ2 (1, N = 557) = 7.70** 
Female > Male 
ns 
To relieve physical 
pain 
57 (41.1) 
94 (51.4) 
68 (49.3) 
110 (65.3) 
57 (55.2) 
100 (72.3) 
χ2 (1, N = 558) = 8.83** 
Female > Male 
ns 
To control coughing 9 (6.4) 
22 (11.9) 
10 (7.3) 
22 (13.2) 
7 (6.5) 
17 (12.3) 
χ2 (1, N = 558) = 4.68* 
Female > Male 
ns 
Note. NMUPD = Non-medical use of prescription drugs. Unweighted sample sizes are reported for the Wald chi-square statistics. * p < .05, 
** p < .01, *** p < .001. 
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College Attendance as a Moderator in Changes in NMUPD Motivations 
Table 7 reports the Wald chi-square statistics for NMUPD motivations which had a main 
effect for college attendance and/or significant moderation (Wave*College Attendance), along 
with the frequencies and percentages of the college attendance differences observed. There only 
were valid significant findings for NMUPD motivation for stimulant medications. Specifically, 
young adults not enrolled in college courses were more likely to endorse the following 
motivations: to relax or relive tension, to feel good/get high, have a good time with friends, and 
to help lose weight.  
GEE models for the following motivations were unable to converge or received an error 
for concerns about validity: addiction and to help study for stimulants, seeking deeper 
understanding, to have a good time with friends, fit in with a group, to decrease the effects of 
other drugs, and addiction for CNS depressants, and to feel good/get high, seeking deeper 
understanding, to have a good time with friends, fit in with a group, to get away from problems, 
to increase the effects of other drugs, to decrease the effects of other drugs, as a substitute for 
heroin, and addiction for opioids. Further, for the motivation, because of anger or frustration, for 
opioid medications, although a significant Wald chi-square was reported for a college attendance 
main effect (χ2 (1, N = 558) = 3.86, p = .049), no significant findings were reported in the subsequent 
pairwise comparisons.   
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Table 7.  
Frequencies and percentages of users by college attendance and wave for significant GEE models, Wald chi-square and pairwise 
comparisons for main effect of college attendance and wave*college attendance 
NMUPD Motivation Wave 1  
Not enrolled:  
n (%) 
Enrolled: 
n (%) 
Wave 2  
Not enrolled:  
n (%) 
Enrolled: 
n (%) 
Wave 3 
Not enrolled:  
n (%) 
Enrolled: 
n (%) 
Wald chi-square for 
college attendance 
Wald chi-square for 
Wave*College 
Attendance 
 
Stimulants      
To relax or relieve tension 34 (14.0) 
38 (9.7) 
30 (10.0) 
16 (5.8) 
21 (7.9) 
3 (2.5) 
χ2 (1, N = 1013) = 8.21** 
Not enrolled > Enrolled 
ns 
To feel good or get high 110 (44.7) 
140 (35.9) 
141 (47.1) 
76 (26.9) 
98 (36.7) 
33 (30.7) 
χ2 (1, N = 1013) = 12.18*** 
Not enrolled > Enrolled 
ns 
To have a good time with my 
friends 
74 (30.3) 
99 (25.3) 
97 (32.3) 
63 (22.3) 
73 (27.6) 
26 (24.5) 
χ2 (1, N = 1013) = 4.48* 
Not enrolled > Enrolled 
ns 
To help me lose weight  87 (35.5)  
116 (29.6) 
117 (38.8) 
64 (22.9) 
98 (37.0) 
30 (28.3) 
χ2 (1, N = 1013) = 7.03** 
Not enrolled > Enrolled 
ns 
Note. NMUPD = Non-medical use of prescription drugs. Unweighted sample sizes are reported for the Wald chi-square statistics. * p < .05, 
** p < .01, *** p < .001. 
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Differences in NMUPD Motivations for Youth who Used in High School Compared to New 
Users at Wave 1 
 Table 8 reports the significant results from logistic regression analyses which estimated if 
new NMUPD users at Wave 1 (coded “1”) reported different motives than individuals who 
reported NMUPD in high school (coded “0”) for each prescription drug class. Participants who 
did not endorse NMUPD in high school were more likely to endorse the following motivations: 
(1) For stimulants: to feel good/get high, to get through the day, to stay awake, to get more 
energy, and to lose weight, (2) for CNS depressants: to feel good/get high, (3) for opioids: to 
relax/relieve tension, to feel good/get high, to get away from problems, to get sleep, as a 
substitute for heroin, and to relieve physical pain. Effect sizes ranged from small (R2 = .008) to 
large (R2 = .075). The motivation most influenced by new NMUPD status at Wave 1 was using 
prescription opioids as a substitute for heroin, with participants who reported no non-medical use 
of prescription opioids in high school 6.06 times more likely to endorse this motivation 
compared to individuals who reported using prescription opioids non-medically in high school. 
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Table 8. 
Significant logistic regression model results, effect sizes, and odd ratios of NMUPD motivations 
for new users at Wave 1 compared to individuals who reported use in high school 
NMUPD Motivation Model Results  
Nagelkerke’s R2 
OR (95% CI) 
Stimulants   
To feel good or get high χ2 (1) = 3.98, p = .046, R2 = .008 1.38 (1.01-1.90) 
To get through the day χ2 (1) = 5.12, p = .024, R2 = .012 1.52 (1.06-2.17) 
To stay awake  χ2 (1) = 5.75, p = .016, R2 = .012 1.50 (1.08-2.09) 
To get more energy  χ2 (1) = 19.73, p < .001, R2 = .042 2.11 (1.52-2.93) 
To help me lose weight  χ2 (1) = 11.39, p = .001, R2 = .025 1.78 (1.27-2.48) 
   
CNS depressants   
To feel good or get high χ2 (1) = 5.05, p = .025, R2 = .022 1.71 (1.07-2.73) 
   
Opioids   
To relax or relieve tension χ2 (1) = 16.99, p < .001, R2 = .068 2.61 (1.64-4.15) 
To feel good or get high χ2 (1) = 4.99, p =.025, R2 = .020 1.68 (1.06-2.66) 
To get away from my problems or 
troubles 
χ2 (1) = 5.81, p = .016, R2 = .030 2.10 (1.15-3.83) 
To get sleep  χ2 (1) = 5.75, p = .017, R2 = .025 1.83 (1.12-2.99) 
As a substitute for heroin χ2 (1) = 4.14, p = .042, R2 = .075 6.06 (0.87-41.67) 
To relieve physical pain χ2 (1) = 5.42, p = .020, R2 = .022 1.71 (1.09-2.69) 
Note. NMUPD = Non-medical use of prescription drugs. No NMUPD in high school = 1, NMUPD 
in high school = 0.  
 
Post hoc analyses for wave 1 NMUPD use comparing young adults who used in high 
school and young adults who initiated use in wave 1. To rule out the alternative explanation 
that engaging in NMUPD in high school is a protective factor in post hoc analyses were 
conducted. Independent t-test analyses were conducted to compare frequency of past year 
NMUPD wave 1 use for young adults who used in high school versus young adults who initiated 
NMUPD in wave 1. As seen in Table 9, results indicated that there were statistically significant 
relations between when young adults initiated NMUPD (in high school versus wave 1) and their 
frequency of NMUPD use at wave 1. Specifically, young adults who reported using any class of 
prescription drug non-medically in high school were more likely to use any other class of 
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prescription drug non-medically at wave 1. Levene’s test for equality of variances was 
significant for all analyses and the results presented are the values when equal variances were not 
assumed. Effect sizes were in general medium range (Cohen’s d: 0.36-0.70), with the highest 
effect sizes in the medium to large range consistently observed for future use of previously used 
prescription drug class (e.g., if used stimulants non-medically in high school, most likely to use 
stimulants at wave 1 compared to other prescription drug classes).  
Table 9. 
Independent t-test results for wave 1 NMUPD use across prescription drug classes comparing 
youth who initiated NMUPD in high school versus initiated NMUPD in wave 1 
NMUPD Frequency Initiated 
NMUPD in 
high school  
(M (SD)) 
Initiated 
NMUPD in 
Wave 1  
(M (SD)) 
t-value df Cohen’s d  
NMUPD Stimulant Users      
Past year stimulant use 2.08 (1.79) 1.13 (0.67) 14.83*** 816.91 0.70 
Past year CNS depressant use 1.35 (1.01) 1.05 (0.34) 8.21*** 812.56 0.40 
Past year opioid use 1.33 (0.98) 1.06 (0.42) 7.58*** 821.84 0.36 
      
CNS depressants      
Past year stimulant use 2.00 (1.76) 1.17 (0.79) 9.91*** 461.81 0.60 
Past year CNS depressant use 1.63 (1.27) 1.04 (0.34) 9.68*** 42.55 0.62 
Past year opioid use 1.46 (1.17) 1.07 (0.43) 7.09*** 453.87 0.44 
      
Opioids      
Past year stimulant use 1.91 (1.68) 1.18 (0.81) 9.19*** 468.55 0.55 
Past year CNS depressant use 1.43 (1.10) 1.06 (0.38) 7.13*** 455.66 0.45 
Past year opioid use 1.68 (1.34) 1.06 (0.38) 9.75*** 448.46 0.63 
Note. NMUPD = Non-medical use of prescription drugs. * p < .05, ** p < .01, *** p < .001. 
 
Changes in NMUPD Motivations Across Young Adulthood for New Users 
Table 10 reports the motivations that had significant differences across waves for new 
NMUPD users at each wave, including the Wald Chi-square statistic and results from the 
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subsequent pairwise comparisons using Bonferroni corrections. Overall, similar to all users, there 
were relatively few motivations that evidenced a main effect of time for new NMUPD users.  
Similar patterns were observed, including the same significant differences between 
waves, for the following motivations of all NMUPD and new NMUPD users by prescription 
drug class: (1) For stimulants, the motivation to experiment decreased less over time, and to get 
more energy increased over time in general; (2) for CNS depressants, to relieve physical pain 
increased over time; (3) for opioids, to experiment decreased over time, and boredom decreased 
over time. Further, for opioids a similar pattern of reporting more of the motivation to relieve 
physical pain was seen between Wave 1 and Wave 3. However, for new users there was an 
additional significant difference between Wave 1 and Wave 2, with increases over time. 
Compared to the results for all NMUPD users, new users had different trajectories of the 
following motivations. For CNS depressants, there were no significant differences found over 
time for the motivation to decrease the effects of other drugs in new users like there was for all 
users. Additionally, new users did report a significant increase between Wave 2 and Wave 3 for 
the motivation to get through the day.  
Additionally, the GEE models for the following motivations were unable to converge or 
received an error for concerns about validity: addiction for stimulants, seeking deeper 
understanding, boredom, and to decrease the effects of other drugs for CNS depressants, and to 
get away from problems, to increase the effects of other drugs, and to decrease the effects of 
other drugs for opioids.   
     
63 
 
Table 10. 
Frequencies, percentages of users, and significant changes in NMUPD motivations across young adulthood for new users 
NMUPD Motivation Wave 1 
n (%) 
Wave 2 
n (%) 
Wave 3 
n (%) 
Wald chi-Square Pairwise comparisons  
Stimulants      
To experiment—to see what it’s like 164 (42.6) 127 (40.7) 42 (29.9) χ2 (2, N = 847) = 16.87*** Wave 1 > Wave 3*** 
Wave 2 > Wave 3** 
To get more energy  193 (53.4) 163 (52.3) 79 (56.3) χ2 (2, N = 847) = 12.45** Wave 1 < Wave 3** 
      
CNS depressants      
To get through the day 9 (4.4) 5 (2.8) 14 (8.9) χ2 (2, N = 446) = 6.29* Wave 2 < Wave 3* 
To relieve physical pain 27 (12.2) 53 (28.1) 43 (27.8) χ2 (2, N = 442) = 6.01* Wave 1 < Wave 2* 
      
Opioids      
To experiment—to see what it’s like 105 (43.6) 71 (33.0) 37 (26.2) χ2 (2, N = 472) = 10.71** Wave 1 > Wave 2* 
Wave 1 > Wave 3** 
Because of boredom, nothing else to 
do 
28 (11.5) 16 (7.6) 13 (9.2) χ2 (2, N = 472) = 10.66** Wave 1 > Wave 2** 
To relieve physical pain 84 (35.1) 101 (47.0) 73 (51.4) χ2 (2, N = 471) = 8.62* Wave 1 < Wave 2* 
Wave 1 < Wave 3* 
Note. NMUPD = Non-medical use of prescription drugs. Unweighted sample sizes are reported for the Wald chi-square statistics. * p < .05, 
** p < .01, *** p < .001. 
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Post Hoc Analyses for NMUPD Motivations 
Latent class analyses (LCAs) were conducted in an exploratory fashion as a potential 
method of data reduction to provide more information for the motivations that were not able to 
be reliably tested with the GEE analyses once moderators were included, likely as a result of 
smaller sample sizes once the data were weighted. However, as suggested in the literature and 
other similar studies (e.g., McCabe & Cranford, 2012), the low frequency motivations were 
removed from the LCAs. Therefore, that data was still not captured. One advantage of LCAs is 
that they are considered person-centered, while GEEs are for estimating the population level 
information (Homish et al., 2010). One strength of this data set is that it is nationally 
representative and there is the potential to look at population-level information. Therefore, it was 
decided that investigating the motives individually provided better insight into this phenomena, 
rather than grouping them together. The results from the LCAs can be provided by the author 
upon request. It should be noted that there were not clear consistent class findings across waves 
for all of the prescription drug classes. 
Discussion 
The present study investigated the developmental changes in NMUPD motivations during 
young adulthood (ages 19 to 24; three waves of data) in a nationally representative sample 
combining data from 1976 to 2013. Additionally, changes in NMUPD motivations by sex, 
college attendance, use in high school, or new user status were researched. NMUPD motivations 
were studied across the prescription drug classes of stimulants, CNS depressants, and opioids. 
Approximately 4-8% of young adults endorsed NMUPD, which was similar to, or slightly lower 
than, other national estimates (e.g., SAMHSA, 2014). Stimulants (e.g., Adderall) were the most 
frequently used prescription drug class in the past year across young adulthood. This suggests 
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that research and interventions targeting the non-medical use of prescription stimulants continue 
to be important endeavors. However, in general, young adults who did endorse NMUPD most 
commonly reported infrequent use (1-5 times in the past year). While the reports of infrequent 
use call into question how problematic NMUPD is on the national level, the known negative 
consequences of NMUPD cannot be ignored (e.g., Arria et al., 2008; Bavarian et al., 2013; 
Janusis & Weyandt, 2010; Lo et al., 2013; McCauley et al., 2009; McCauley et al., 2010; 
McCauley et al., 2011; Van Eck et al., 2012; Zullig & Divin, 2012). Future work should 
thoroughly investigate what are the predictors and mechanisms of problematic NMUPD, 
specifically by prescription drug class, to get a better understanding of how frequency of 
NMUPD relates to the reported adverse outcomes.  
Below, the results are reviewed in terms of the hypotheses and previous research. Areas 
of future research in relation to each major finding are discussed. Unique and unexpected 
findings are highlighted. Limitations of the current study, emerging research questions, and 
general conclusions close the section. Key findings from this study were that both recreational 
and self-treatment motivations were commonly reported over time and across drug classes, 
suggesting a need for multifaceted treatments. Generally, NMUPD motivations remained 
relatively stable across young adulthood. The motivations of experimentation and boredom 
decreased for some drug classes, and increased in select self-treatment motivations. Overall, men 
were more likely to endorse recreational motivations, while women were more likely to endorse 
self-treatment motivations, with some exceptions by prescription drug class. Women also were 
more likely to report using prescription stimulants non-medically to lose weight. Young adults 
not enrolled in college courses were more likely to endorse using stimulants non-medically for 
different reasons than their peers who were enrolled. There also were differences in motivations 
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based on if young adults initiated NMUPD in high school compared to when they were 19 to 20 
years old. Yet, there were not many differences in NMUPD motivations across young adult 
development for new users.  
Programs which target the most popularly endorsed NMUPD motivations will likely be 
successful in reducing NMUPD across young adult development for new and continued users. 
However, to be the most effective, efforts focusing on reducing NMUPD may need to be adapted 
by prescription drug class, sex, and college attendance status. Prevention efforts which start in 
high school may be useful in reducing NMUPD in the young adult population.  
Descriptive Findings and Implications 
Certain motivations were popular across the three waves of data for NMUPD and the 
majority of young adults endorsed multiple motivations, leveling off around four to five reasons 
for engaging in NMUPD. For stimulants the motivations endorsed primarily were educational 
enhancement (i.e., to help me study), and the clinical reasons the medications are prescribed, or 
self-treatment motivations (i.e., to stay awake, to get more energy). Recreational motivations 
(i.e., to feel good or get high, to experiment) and weight loss rounded out the stimulant category. 
For CNS depressants, NMUPD motivations focused mainly around self-treatment (i.e., to relax 
or relieve tension, to get sleep), recreational motivations (i.e., to feel good or get high, to 
experiment), and for the side-effect of pain relief. For the non-medical use of prescription 
opioids the commonly reported motivations included recreational (i.e., to feel good to get high, 
to experiment) and self-treatment motivations (e.g., to relax or relieve tension, to relieve physical 
pain). The results give support to both the self-medication hypothesis and Arnett’s theory on 
recreational substance use in emerging adulthood (Arnett, 2005; Duncan,1974a; 1974b; 1975; 
Khantzian, 1985; 1997). Given the variety of motivations endorsed for NMUPD, prevention and 
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intervention efforts should be multifaceted to address the different motivations. Since, across 
prescription drug classes, both self-treatment and recreational motivations were commonly 
reported, both need to be included in prevention and intervention efforts. Additionally, there may 
be a need to design specific interventions based on each drug class’s inherent properties and 
clinically prescribed effects, as well as popular side effects (e.g., weight loss for stimulants and 
physical pain relief for CNS depressants).  
Interestingly, the percentages of NMUPD users attending college classes decreased over 
time for all prescription drug classes. This suggests that young adults who engage in NMUPD 
may be at more risk for college drop out. On the other hand, there may be other confounding 
factors (e.g., mental or physical health issues, Huang et al., 2006) that makes attending college 
classes difficult for this population and NMUPD more likely, and is an area of future research. 
This finding complements other work that has found that college students who endorse the non-
medical use of prescription stimulants and opioids spent less time studying, skipped classes more 
often, and earned lower grades compared to their non-using peers (Arria et al., 2008). These 
factors may explain the observed reduction in college attendance over time. The results from the 
present study also suggest that similar risk factors may be relevant for college students who use 
CNS depressants non-medically. Additionally, future work need to consider graduation rates 
which may also explain the low numbers of college attendance, particularly when the sample is 
23 to 24 years old. 
Changes in NMUPD Motivations Across Young Adulthood 
In terms of the main aims of the study, according to GEE models, motivations to engage 
in NMUPD were relatively stable over time. As a result, many of the study’s hypotheses about 
overall changes in NMUPD motivations across young adulthood were only partially supported, 
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and in general, varied by prescription drug class. The prediction that was most accurate was that 
there would be no change over time for following motivations: to seek deeper insights and 
understanding, because of anger or frustration, to get through the day, to increase the effects of 
some other drug(s), to decrease (offset) the effects of some other drug(s), as a substitute for 
heroin, and to control coughing. The only time this hypothesis was not supported was for CNS 
depressants, where to decrease the effects of some other drug(s), was found to increase between 
wave 1 and wave 3. This finding proposes that CNS depressants may be more likely to be 
combined with other drugs, especially as young adults get older. This may be because as young 
adults age they become exposed to a greater variety of substances, and therefore they are more 
likely to be combing drugs. Indeed in young adult and college student samples, those who 
engage in NMUPD were more likely to endorse using other drugs, binge drinking, and 
combining their prescription drugs with other substances (Advokat et al., 2008; Barrett et al., 
2005; Garnier et al., 2009; McCabe et al., 2007; McCabe et al., 2009; McCabe et al., 2006; 
SAMHSA, 2006). These behaviors increase the risk of potentially dangerous drug interactions 
and their negative outcomes. Specifically with CNS depressants, the disinhibitory and aggressive 
effects that result in violence and assault, as well as the risk for opioid-related deaths, are 
increased when CNS depressants are combined with alcohol and other drugs (Jann et al., 2014; 
Lader, 2011; Webster et al., 2011). Additionally, as this suggests that young adults are using a 
variety of drugs, treatment programs may not be effective if they are only targeting NMUPD. 
More research needs to be conducted in understanding how NMUPD fits into the larger drug 
culture, and how and why using CNS depressants to regulate the effects of other drugs increases 
overtime, while the use of stimulants and opioids to regulate the effects of other drugs remain 
more stable.  
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It was predicted that for recreational motivations, like to feel good or get high, for 
experimentation, and boredom, would decrease over time across all prescription drugs classes as 
young adults move towards more stability based on Arnett’s theory of emerging adulthood 
(Arnett, 2005). This hypothesis also was partially supported. The NMUPD motivation of 
experimentation decreased across young adulthood for stimulant and opioid medications. 
Additionally, the NMUPD boredom motivation decreased between wave 1 and wave 2 for opioid 
medications, and was stable between waves 2 and 3. These findings support Arnett’s theory that 
as young adults age they are less likely to use substances for recreational reasons as part of the 
self-exploration process and instability experienced during this this developmental period 
decreases. As a result, targeting these more recreational motivations may be more appropriate 
when individuals are entering young adulthood; at least for stimulant and opioid medications.  
On the other hand, using prescription drugs non-medically to feel good or get high was 
consistent over time and a popularly endorsed motivation across prescription drug classes (i.e., 
reported by 35-55% of users). This should remain a target of intervention across young 
adulthood. The popularity and consistency of this motivation calls into question parts of Arnett’s 
theory (2005) which would suggest that young adults would engage less in NMUPD to feel good 
or get high as they become more stable and potentially experience less stress and optimism. 
Additionally, according to research on brain development around this age, young adults should 
have the cognitive capacity to make methodical decisions over emotion-driven decisions (e.g., 
Steinberg, 2008), which would decrease this emotionally related motivation. Therefore, more 
work needs to be conducted to see if by age 24 young adults are actually experiencing less stress 
and negative affect associated with disruptions in life as proposed (e.g., new romantic partners, 
educational and vocational settings). Since much research has found that many young adults feel 
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like they are reaching “adulthood” later and later as traditional markers of adulthood are being 
continually delayed (e.g., getting married, buying a house, bearing children; Hutchison, 2015), 
this motivation may not actually decrease until later than the age range investigated in this study 
(e.g., 30 years old, Arnett, 2000). This could be tested using later cohorts from the MTF study as 
more data becomes available in later follow-up waves. 
It was also predicted that “self-treatment” motivations (e.g., using the medications as they 
are clinically intended) and addiction motivations would increase over time across all 
prescription drug classes as exposure to prescription drugs and the risk for psychiatric problems 
increases (e.g., Kessler et al., 2005), under the self-medication hypothesis (Duncan, 1974a; 
1974b; 1975; Khantzian, 1985; 1997). Again this hypothesis was partially supported in all 
prescription drug classes. For stimulants, to get more energy was endorsed more in wave 3 
compared to wave 1. In reference to CNS depressants and opioids, to relieve physical pain 
increased over time (between wave 1 and wave 2 for CNS depressants, and wave 1 and wave 3 
for opioids). This suggests that more outreach may be needed as young adults age to counter 
these motivations. Also, prevention may be possible in early young adulthood by using evidence-
based treatments to target these motivations. For example, introducing and promoting ways to 
increase energy through the use of exercise (Haskell et al., 2007), or to decrease physical pain 
through the use of evidence based treatments (e.g., Garg, Joshi, Mishra, & Bhatnagar, 2012), 
may help to prevent young adults from engaging in NMUPD. Future research on how to continue 
to target these motivations in ways that have less potentially dangerous and harmful effects 
compared to NMUPD, are user-friendly, and accessible to young adults continues to be 
important.  
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However, other self-treatment motivations (i.e., stimulants: to stay awake, to help study, 
and to lose weight; CNS depressants: to relax or relieve tension and to get sleep; and opioids: to 
relax or relieve tension, and to get sleep) were stable across the three waves of data collection. 
This is not to say that these motivations are not important treatment targets, as many are 
commonly reported as motivations by this population. Rather, because these self-treatment 
motivations remain stable over time targeting them throughout young adulthood is vital.  
Again, making alternative methods of treatments available beyond NMUPD is necessary. 
Connecting young adults to mental health professionals who can accurately diagnose and 
prescribe appropriate treatments, including medications, may help to alleviate these symptoms 
while reducing the risks associated with NMUPD, including the potential negative interactions of 
ingesting different substances when not being followed by a medical professional (McCabe et 
al., 2009). This is especially important as young adults may also misdiagnose their symptoms, 
resulting in use of inappropriate medications which in turn may lead to making their underlying 
problem worse, not better (Holloway & Bennett, 2012). 
Moreover, using prescription CNS depressants and opioids medications as a sleep aid 
was endorsed as a relatively common motivation, and to get more energy and to stay awake was 
noted as a common motivation for stimulants. Given that the effects of taking medications to 
reduce sleep problems have been shown to decline in effectiveness over time and there is 
increasing research that supports such protocols as cognitive-behavior therapy as evidence-based 
treatments for disorders like insomnia (Morin, 2010), assessing and targeting sleep problems 
may be an effective prevention and intervention tool for reducing NMUPD in young adults. 
Additionally, as there is evidence that young adults who use prescription stimulants non-
medically report worse subjective and overall sleep quality, as well as more sleep disturbances 
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compared to their peers who do not endorse non-medical use of stimulants (Clegg-Kraynok et 
al., 2011). As a result, targeting sleep problems may be beneficial to all young adults non-
medically using prescriptions, regardless of prescription drug class. 
Further, the addiction motivation did not vary across young adult development. One 
reason for this finding may be the low percentage of participants who endorsed addiction as a 
motivation, especially for stimulant medications (endorsement ranged from 1.1% to 9.5% of 
users). The number of young adults reporting addiction as a motivation for the non-medical use 
of prescription stimulants was so low the GEE model was unable to converge. There are a few 
potential reasons for why the addiction motivation was endorsed at such a low level across 
prescription drug classes. One may be that certain prescription medications have less addictive 
properties. In particular, stimulants medications are known to be less addictive as compared to 
opioids and CNS depressants (e.g., NIDA, 2011). Alternatively, individuals in this population 
may lack insight into their motivations and the potential that they are addicted to these 
medications, or are responding in a socially desirable manner. However, given that most of the 
sample reported infrequent use, another conclusion could be that not many individuals are 
addicted to the medications investigated. This also may explain the low numbers of young adults 
seeking treatment (e.g., 3.5% to 10.3%; McCabe et al., 2009), although more have been seeking 
treatment over time (e.g., SAMHSA, 2011). The results from this study suggest that targeting 
addiction as a motivation for use may not be as effective as targeting other motivations for use. 
Further, other treatment models that tend to focus on the addictive qualities of substances (e.g., 
many twelve-step programs, Arria & DuPont, 2010) may not be as appropriate for this 
population of substance users. Research needs to investigate though whether young adults 
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endorsing recreational motives report improved outcomes from receiving such treatments (Arria 
& DuPont, 2010).  
Sex Effects on NMUPD Motivations in Young Adults 
 This study also investigated the role of sex in NMUPD motivations and if sex moderated 
the changes in NMUPD motivations across young adulthood using GEE models. It should be 
noted, that some of motivations were unable to investigated in this sample as the GEE models 
were unable to converge or received an error for concerns about validity. In general, the 
hypothesis that more males would endorse recreational motivations compared to females was 
supported. Specifically, significantly more males endorsed recreational motivations for 
stimulants (i.e., experimentation, have a good time with friends, increase the effects of other 
drugs, decrease the effects of other drugs). Males also were more likely than females to be 
motivated to use prescription stimulants non-medically stay awake. Similarly, for CNS 
depressants and opioids, more males endorsed the following recreational motivations: 
experimentation, to feel good/get high, and have a good time with friends. These findings are 
similar to previous work that found that males were more likely to endorse recreational and 
mixed motivations (both recreational and self-treatment motivations) compared to females in 
varied samples of higher education students (Lord et al., 2011; Lord et al., 2009; McCabe et al., 
2007; McCabe et al., 2009). These findings support the generalization of this sex difference to 
the larger young adult population. 
Conversely, as generally predicted, more females reported self-treatment motivations, or 
using the medications as they are clinically intended, compared to males for CNS depressants 
and opioids, similar to previous work (Lord et al., 2011; McCabe et al., 2007; McCabe et al., 
2009). More females endorsed being motivated to use CNS depressants and opioids non-
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medically to get sleep as well. Further, more females endorsed using opioids non-medically as 
well to relieve physical pain and to control coughing. For stimulant medications, females did not 
report more self-treatment motivations, which also was found in one other study (McCabe et al., 
2009). Again, the sex differences found in smaller samples of young adult students appears to 
hold true for the greater young adult population.  
As a result, it is advisable that prevention and intervention efforts may be more effective 
if they are sex-specific. Programs for males could focus more on recreational motivations, while 
programs for females could focus on more self-treatment motivations. Efforts to reduce NMUPD 
in males should emphasize other methods to engage in recreational activities or promote positive 
risk-taking experiences that have less negative consequences associated with them (e.g., 
recreational sports leagues). Research on the effectiveness of these alternative approaches needs 
to be explored further. Focus groups including males who do and do not engage in NMUPD may 
help researchers and practitioners discover some of the different methods used in these 
populations to achieve the same recreational goals. On the other hand, programs for females may 
include more evidence-based approaches for sleep and pain improvement as previously 
discussed. Additionally, connecting females to mental health professionals to target the 
underlying symptoms may be more appropriate.  
Moreover, more females endorsed using stimulants non-medically to lose weight. This 
contradicts previous work on this topic which found similar reports of using stimulants non-
medically for weight loss purposes (Jeffers et al., 2013; Jeffers & Benotsch, 2014). However, 
this research was conducted at one university, which may limit the studies’ findings. The results 
from this nationally representative sample highlights that this finding may not be true for the 
broader young adult population. This result is not surprising though, given that in the general 
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population, young adult females tend to report more concerns about weight loss, using multiple 
methods to achieve weight loss, and are diagnosed with more eating disorders (Wilson, Grilo, & 
Vitousek, 2007). Given that weight loss was reported by 31% to 35% of non-medical stimulant 
users this is a significant motivation to include in prevention and intervention efforts, specifically 
treatment groups that are aimed at treated young adult female populations. Programs that have 
been found to be effective in making healthy lifestyle changes in young adults, specifically with 
weight loss as an outcome (e.g., Anderson, Konz, Frederich, & Wood, 2001), could be effective 
in this population to reduce using prescription stimulants non-medically for weight loss reasons.  
There were two motivations where sex moderated the changes in NMUPD motivations 
over time: to feel good/get high for stimulant medications and to have a good time with friends 
for CNS depressants. In particular, females in wave 3 (ages 23/24) were less likely to report the 
motivation to feel good/get high for the non-medical use of stimulants compared to females in 
wave 1 (ages 19/20) and males in wave 3. Furthermore, males in wave 2 (ages 21/22) were more 
likely to endorse the motivation to have a good time with friends for CNS depressant non-
medical use compared to both wave 1 and wave 2 females. Even though protections against Type 
I errors were implemented, given the paucity of moderation findings it is possible that these 
results are more likely the consequence of chance, and should not be emphasized. However, as 
these select findings highlight more recreational motivations, they are in line with previous work 
that as young adults age they may become more mature and engage in NMUPD less frequently 
for recreational reasons (Arnett, 2005). Further, these results support research on sex differences 
on risk-taking behaviors in adolescence and young adulthood where females have been found to 
mature more quickly in their decision making processes as compared to males (e.g., Harris, 
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Jenkins, & Glaser, 2006). Future studies need to replicate these results before heavily weighing 
the implications.  
College Attendance Effects on NMUPD Motivations in Young Adults 
Differences in young adults’ NMUPD motivations based on college attendance were 
researched as well using GEE models. Results from the CNS depressant and opioid prescription 
drug classes supported the hypothesis that that college attendance would not moderate the 
relations of change in motives over time because young adults in and out of college both 
experience the same developmental life stage and associated changes, which provides support for 
general theories on young adult development (Arnett, 2005). However, there were general 
differences in NMUPD motivations for young adults in regards to the non-medical use of 
prescription stimulants, though no moderation was found. The one study that included a 
significant sample of young adults both enrolled and not enrolled in college classes found that, in 
general, the sample reported using stimulants non-medically both as the medications were 
intended and for recreational purposes, similar to studies of solely college students (Upadhyaya 
et al., 2010). However, this study did not specifically examine differences in NMUPD 
motivations by college attendance. The present study found that young adults not enrolled in 
college courses were more likely to endorse using stimulants non-medically to relax or relive 
tension, to feel good/get high, have a good time with friends, and to help lose weight. Notably, 
none of the motivations reported more by young adults not enrolled in college courses were 
using the medications as they are clinically intended. This highlights that young adults not in 
college may be at higher risk for using stimulants non-medically for unique reasons and 
alternative ways to directly address these motivations may be needed. Future research needs to 
continue to include young adults not in college to verify these findings. Also, since a variety of 
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motivations were unable to be reliably run, research needs to look more closely at some of the 
less reported motivations and in CNS depressant and opioid prescription drug classes.  
High School NMUPD Users Have Different Motivations and Risk Factors 
To gain a better understanding changes in motivations during the early young adulthood, 
logistic regression analyses revealed that young adults who started NMUPD at wave 1 (ages 
19/20), compared to those who started NMUPD in high school, were more likely to endorse the 
following motivations: (1) For stimulants: to feel good/get high, to get through the day, to stay 
awake, to get more energy, and to lose weight, (2) for CNS depressants: to feel good/get high, 
and (3) for opioids: to relax/relieve tension, to feel good/get high, to get away from problems, to 
get sleep, as a substitute for heroin, and to relieve physical pain. Consequently, young adults who 
engage in NMUPD for the first time when they are 19 to 20 years old appear to be motivated by 
different factors compared to young adults who had previous NMUPD exposure in high school. 
Both recreational and self-treatment motivations were noted in different prescription drug classes 
and therefore, these results only partially supported the hypothesis that young adults who initiate 
NMUPD shortly after high school would be more likely to endorse recreational motivations.  
In reference to the differences in recreational motivations that were found, it is possible 
that there is less novelty for individuals who engage in NMUPD at earlier ages. Specifically, the 
recreational motivation to feel good/get high was more likely to be reported by new wave 1 users 
across all prescription drug classes and highlights an important commonality. One reason this 
motivation may be more prevalent in new users is that young adults who reported NMUPD in 
high school may be experiencing some tolerance effects (e.g., Rosenfield et al., 2011). Since to 
feel good/get high is so widespread, prevention interventions for 19 to 20 year olds that target 
this motivation will likely be effective across prescription drug classes.  
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Other motivations that were reported more by new wave 1 users suggest that self-
treatment needs may be higher in this population compared to young adults who used in high 
school. As young adulthood is when many mental health illnesses emerge (Kessler et al., 2005), 
it is not surprising that self-treatment motivations are more popular. This may also imply that 
those who use NMUPD in high school may have different symptom profiles and needs compared 
to individuals who start NMUPD later. This needs to be further investigated by future 
researchers. Regardless of whether young adults are treating actual symptoms, the theme of self-
treatment suggests that young adults are not receiving the proper medical and mental health 
treatment needed. This may be occurring for a variety of reasons including stigma around 
receiving treatment, previous negative treatment experiences, limited access to health care, 
and/or a lack of awareness that NMUPD is a problem (Lord et al., 2011). Additionally, young 
adults may not have the resources to cope with stressors in more adaptive ways. Fostering 
support systems, like study or treatment groups, and suggesting adaptive coping strategies like 
proper diet and exercise, may help young adults better manage their stress (Herman et al., 2011). 
All of these potential problems could be addressed with prevention and intervention strategies, 
and may be needed more as individuals transition from adolescence to young adulthood. Future 
research should not only assess why there is a treatment gap, but funding should be provided for 
studies investigating the effectiveness of targeting these different barriers to treatment. 
Interestingly, the motivation most influenced by new NMUPD at wave 1 was using 
prescription opioids as a substitute for heroin, with participants who reported no non-medical use 
of prescription opioids in high school 6.06 times more likely to endorse this motivation 
compared to individuals who reported using prescription opioids non-medically in high school. 
One explanation for this may be that these individuals were first using heroin in high school and 
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then initiated prescription opioid use in early adulthood. Although, much of the research to date 
suggests the opposite relation, that individuals who inject heroin are more likely to report the 
misuse of prescription opioids first (Brands, Blake, Sproule, Gourlay, & Busto, 2004; Cicero, 
Ellis, Surratt, & Kurtz, 2014; Cicero, Ellis, & Surratt, 2012; Grau et al., 2007; Lankenau et al., 
2012; Peavy et al., 2012; Pollini et al., 2011); this highlights the need for work to also research 
the alternative direction. At least one investigation, where the authors pooled data from the 
National Survey on Drug Use and Health, did research the alternative hypothesis. While 
individuals who used heroin before using prescription opioids non-medically were at an 
increased risk for NMUPD, the risk was much greater in the opposite direction, from the non-
medical use of prescription opioids to heroin (2 times more likely versus 19 times more likely, 
respectively; Muhuri, Gfroerer, & Davies, 2013). However, these findings highlight that 
reducing heroin use may consequently also lead to a reduction in the non-medical use of 
prescription opioids. This may be particularly salient for adolescents who use heroin in high 
school. However, the timing of use of heroin versus prescription opioids is not completely clear 
in this study, as the use is surveyed in the past year. More research on the specific timing and 
interplay of these two illicit substances needs to occur.  
It is important to recognize that NMUPD in high school was a risk factor for further 
NMUPD in the following two years, based on frequency data. Post hoc analyses revealed that 
those individuals who reported NMUPD for any prescription drug class in high school were 
more likely to endorse NMUPD across all prescription drug classes at wave 1. Importantly, if a 
participant used a particular class of prescription drugs in high school, the strongest effects were 
for future use of that drug class (e.g., if used stimulants in high school had stronger effect sizes 
for future stimulant use compared to other drug classes). This suggests that targeting NMUPD in 
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high school could prevent increased use of NMUPD in early young adulthood, even if rates of 
NMUPD are lower during adolescence (SAMHSA, 2013b). Further, it does not appear that the 
interventions need to target any one specific prescription drug class. Instead, targeting one or all 
of the drug classes studied would probably reduce the risk of NMUPD across the board.  
Motivations to Initiate Use Similar to Motivations of General Use Across Young Adulthood 
Finally, what motivates young adults to initiate NMUPD across young adult development 
was studied using GEE models. In general, similar to all users, there were relatively few 
motivations that changed over time for new NMUPD users. Additionally, motivations that did 
change most often reflected the changes observed in all users. This supports the hypothesis that, 
overall, young adults experience the same changes in motivations over time because they are all 
experiencing the same developmental life stage and associated changes, which support Arnett’s 
(2005) theory. A few differences in motivations were found between all users and new users, but 
these were sparse and there were none for the non-medical use of prescription stimulants. 
Specifically, for new non-medical users of prescription opioids along with increases in the 
motivation to relieve physical pain between wave 1 and wave 3, new users also reported an 
increase between wave 1 and wave 2. For CNS depressants, there were no significant differences 
found over time for the motivation to decrease the effects of other drugs in new users like there 
was for all users. Additionally, new users did report a significant increase between wave 2 and 
wave 3 for the motivation to get through the day. While these findings highlight areas for 
potential future research, the findings need to be interpreted with caution before they are 
replicated. Since two of the findings found more significant differences between more waves, 
and in the previously observed direction, this could mean that new users report these motivations 
on a sharper slope. In other words, new users may feel the need to relieve physical pain by using 
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prescription opioids or to get through the day by using CNS depressants more frequently than all 
users. New users may also be at less risk for combining CNS depressants with other drugs. This 
may be because new users are less experienced with drugs in general and are therefore less likely 
to be combining substances.  
Limitations and Future Research 
As with all research, this study has limitations that need to be acknowledged and ideally 
addressed in future work. First, this study was secondary data analysis of a reduced data set 
which limited the types of questions and confounding variables that could be assessed. Future 
work needs to consider other factors that may influence NMUPD motivations in this population 
including other demographic factors (e.g., geographic location, GPA, race/ethnicity, etc.) and 
other known risk factors for drug use (e.g., stress, trauma, other drug use, etc.). Second, the 
current study only assessed frequency of NMUPD and does not include measures of problematic 
NMUPD. Since most of the sample reported infrequent use, investigating measures of 
problematic use will likely lead to more bountiful information on which motivations may be 
most appropriate to target to make the most impact. Additionally, even with a large data set 
NMUPD frequency were low once the data were weighted, and consequently so were some of 
the reported motivations for use, resulting in difficulties for gaining a thorough understanding of 
the less frequently endorsed motivations. However, more research needs to be conducted about 
the importance of motivations that are less frequently reported. Spending energy and resources 
on these motivations may not be as useful on a larger scale compared to focusing on NMUPD 
motivations that are more common in young adulthood. Future work using factor analyses or 
other methods of data reduction may be helpful in determining how these motivations may group 
together in a clinically relevant way. To increase the sample size for this study multiple cohorts 
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were combined from 1976 to 2013, but cohort effects were not assessed as part of this work. 
Given the changes in NMUPD frequency (e.g., Lipari et al., 2015) and the increasing availability 
of prescription drugs overtime (Yu, 2012), research needs to look at how that may influence this 
study’s findings. This study also relied on self-reports which are subject to social desirability and 
call into question the accuracy of participants’ reports of negative behaviors, like drug use 
(Kazdin, 2003). Some studies that have not looked at motives have used unique methods in 
assessing NMUPD including testing campus wastewater for evidence of stimulant medication 
use in college populations (Burgard, Fuller, Becker, Ferrell, & Dinglasan-Panlilio, 2013). These 
innovative and other more traditional approaches, like using other reporters, should be 
considered in future work. This research leaves some other emerging questions unanswered. 
These include: How different is NMUPD from other drug use? Are current treatments targeting 
these motivations and do they work; specifically for young adults? Are there cultural similarities 
and differences in NMUPD motivations across countries? Researchers and advocates for the 
prevention of NMUPD in young adults should address these emerging areas while considering 
the current findings and concerns of prior research.  
Conclusion 
 Even with these limitations acknowledged, the current study had several strengths 
including being the first work to investigate the changes in NMUPD across young adulthood in a 
nationally representative sample. Results from this study need to be replicated, but can be 
generalized to the American young adult population. As NMUPD motivations were generally 
stable over time the best approach to targeting NMUPD based on motivations will be to address 
the motivations endorsed the most frequently over time. However, since endorsing more than 
motivation was common, these interventions need to be multifaceted. Prevention and 
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intervention programs may need to be specialized by sex, and should start in high school to 
prevent future use. Young adults both enrolled and unenrolled in college classes need to be 
targeted, but those not enrolled in college classes may have different motivation patterns, at least 
in terms of stimulant medications. Programs should address these differences and be tested for 
their effectiveness.  
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